The S&P 500 (^GSPC -0.06%) has had a great year so far. The average annual return of the S&P 500 is about 10%, and with it sitting at about 14.5% right now, it has been a good year. There are still a few months left, so the chances of it ending up even higher are quite good.
While the S&P 500 as a whole is doing well, a few individual performers stand out. Sandisk holds the title for best-performing S&P 500 stock this year, rising about 590% in 2026. Intel is another top performer, increasing nearly 200% so far this year. There are a handful of companies that also have had strong runs, including AMD.
So, which stock will lead the S&P 500 higher next year? I think it will be a familiar face, and it won't be one of these three.
Image source: Getty Images.
Some stocks have gotten ahead of themselves With the returns some stocks are delivering this year, it's pretty easy to guess that next year may not be as kind to these stocks. Many companies have far outgrown their business results and are trading at inflated valuations, such as Intel and AMD. These two trade for 70 and 81 times forward earnings, respectively. This showcases just how expensive they are. Others, like Sandisk, operate in a cyclical market, and the stock market is wary of giving it a standard valuation due to fears of the memory chip industry seeing a cyclical downturn.
Premium Feature
Moneyball Superscore
95/100
Today's Change
(
-2.28
%) $
-13.86
Current Price
$
594.24
Regardless, there are a handful of stocks that were abandoned to pave the way for these to rise, and the most obvious one is Nvidia (NVDA -1.29%). Nvidia led the S&P 500 in performance during 2023 and 2024, and I think it has a strong shot at leading it again in 2027. Why? Its stock has been ignored compared to some of its peers.
Nvidia is dirt cheap compared to its peers It's hard to say that the largest company in the world by market cap isn't getting a fair shake, but that's exactly what's happening. As mentioned above, AMD trades at over 80 times forward earnings. Nvidia trades at 25.
AMD PE Ratio (Forward) data by YCharts
These two companies operate in the same industry (namely, graphics processing units, or GPUs), and Nvidia is growing its data center business (the segment most exposed to artificial intelligence (AI)) at a faster pace. In Q2, Nvidia's data center division grew at a 117% pace to $89 billion. AMD's data center division grew at a 107% pace to $6.7 billion. Nvidia is still winning, and there's no reason to give AMD a ridiculous premium as a result.
Another factor is that the market hasn't priced in practically any of 2027's growth into Nvidia's stock price. The S&P 500 trades for about 20 times forward earnings. The slight premium Nvidia now commands is worth it given its positioning in the AI boom and strong track record of performance. However, Nvidia is also expected to grow its revenue by 70% next year. But Nvidia's current 25 times forward earnings valuation implies that its stock will grow at a market-average pace next year (about 10%).
Premium Feature
Moneyball Superscore
97/100
Today's Change
(
-1.29
%) $
-2.96
Current Price
$
226.32
That's a major mismatch, and I think it suggests Nvidia is poised for an exceptional year and could lead the S&P 500 in performance. While there could be others that sneak up on investors and outperform Nvidia, Nvidia is one of the few companies that has given investors high visibility into its future growth. Management has undergirded nearly every step along the way, so this 70% growth could also be a major undershoot.
With Nvidia expected to grow revenue by 70% or more next year, I think it's a no-brainer buy right now.
TORRANCE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies, today announced its latest 24 kW, 800 V-to-12 V DC-DC power delivery board (PDB), powered by GaNFast™ technology and developed in collaboration with NVIDIA, to support the NVIDIA MGX ecosystem and advance 800 VDC power architectures for AI data centers. The new PDB is planned to be featured on NVIDIA’s AI Factory MGX Wall partner display area at OCP Global Summit 2026.
This latest 24 kW, 800 V-to-12 V PDB extends Navitas’ portfolio of 800 VDC AI data-center platforms, building on the previously announced 20 kW, 800 V-to-6 V PDB developed in collaboration with NVIDIA. These solutions advance the core strategic focus of the Navitas 2.0 transformation to accelerate the replacement of legacy silicon with next-generation GaN and SiC high-power technologies across AI infrastructure, from Grid-to-xPU.
The PDB is capable of delivering 24 kW with a target efficiency of 97% at full load and a power density exceeding 2,000 W/in³, providing power for the entire compute tray. Designed in NVIDIA’s latest 400 mm × 60 mm form factor, the PDB can be integrated onto the compute motherboard as close as possible to the xPUs, minimizing power-delivery losses and supporting high-power demands.
The single-stage architecture converts 800 VDC directly to 12 VDC, eliminating the existing 50 V-to-12 V IBC conversion stage and delivering 12 V directly to the voltage regulator module (VRM) that powers the xPU. This simplified power architecture improves system efficiency and reliability while reducing power losses, board space and overall power-delivery complexity.
The power architecture incorporates 16 × NV6034 (650 V, 18 mΩ) GaNFast™ FETs on the primary side, configured in a stacked half-bridge topology and featuring Navitas’ latest dual-cooled DFN 8 × 8 package.
“The next era of AI will be defined not only by how much compute we can create but by our ability to deliver the power needed to unleash its full potential,” said Chris Allexandre, President and CEO of Navitas. “Our collaboration with NVIDIA is breaking the AI infrastructure power wall by reimagining power delivery from 800 VDC to the GPU. This next-generation 24 kW solution demonstrates how GaNFast™ technology can eliminate power-conversion stages, increase efficiency and power density, and bring power closer to the GPU.”
Navitas’ portfolio of 800 VDC AI data-center platforms provides customers with greater flexibility to select the optimal intermediate-bus voltage and VRM architecture for their point-of-load power requirements.
The 800 V-to-12 V PDB is planned to be showcased at the NVIDIA AI Factory MGX Wall partner display area at OCP Global Summit 2026. For more information, please contact your Navitas representative or email [email protected].
About Navitas
Navitas Semiconductor (Nasdaq: NVTS) is a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies for AI infrastructure, including data centers and energy and grid systems, as well as additional markets such as high-performance computing and industrial electrification. Collectively, these technologies address the complete grid-to-xPU power architecture, breaking the AI infrastructure power wall and enabling higher efficiency, greater power density, and increased performance across the entire power chain. Navitas’ GaNFast™ FETs deliver industry-leading power density, efficiency, and high-speed performance, while GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection to enable faster, more efficient power conversion, leading to smaller and more reliable systems. The GeneSiC™ portfolio combines proprietary trench-assisted planar (TAP) SiC technology with leading-edge discrete packaging and SiCPAK™ power modules to deliver industry-leading efficiency, ruggedness and performance. Claros™ IVR technologies extend power delivery directly to the xPU, enabling customers to implement vertical power delivery (VPD) and embedded power delivery (EPD) architectures with high-density power conversion beneath or within millimeters of the processor, minimizing power-delivery losses and impedance while enabling ultra-fast transient response, higher efficiency and maximum power density. Navitas has over 450 patents issued or pending and is a leader in 800 VDC and the advanced AI power infrastructure ecosystem.
Navitas®, GaNFast®, GeneSiC™, Claros™, SiCPAK®, GaNSafe®, DrGaN™, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited or affiliates. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are attempts to predict or indicate future events or trends or similar statements that are not a reflection of historical fact. Forward-looking statements may be identified by the use of words such as “we expect” or “are expected to be,” “estimate,” “plan,” “project,” “forecast,” “intend,” “anticipate,” “believe,” “seek,” or other similar expressions. Forward-looking statements are made based on estimates and forecasts of financial and performance metrics, projections of market opportunity and market share and current indications of customer interest, all of which are based on various assumptions, whether or not identified in this press release. All such statements are based on current expectations of the management of Navitas and are not predictions of actual future performance. Forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions and expectations. Many actual events and circumstances that affect performance are beyond the control of Navitas and, forward-looking statements are subject to a number of uncertainties. Our businesses are subject to certain risks that could materially and adversely affect our respective business, financial condition, results of operations, or the value of our securities. For Navitas, these and other risk factors are discussed in the Risk Factors section of our most recent annual report on Form 10-K, as updated in the Risk Factors section of our most recent quarterly report on Form 10-Q, and in other documents we file with the SEC. If any of these risks, as discussed in more detail in our SEC reports, materialize or if our assumptions underlying forward-looking statements prove to be incorrect, actual results could differ materially from the results implied by these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/add83c1f-3ef4-4e7e-b06a-5c20838cf2c2
Navitas Collaborates with NVIDIA on 800 V-to-12 V Power Delivery Board for Next-Generation AI Infras... Next-generation 24 kW power delivery board converts 800 VDC directly to 12 VDC in a single stage, el...
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula.1 The prespecified subgroup analyses from the FUZION study are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population.
In the overall study population, 28% of patients receiving TREMFYA 100 mg q8w and 27% receiving TREMFYA 200 mg q4w achieved the composite endpoint of combined fistula remissiona at Week 24, compared with 10% receiving placebo, making TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial in patients with Crohn's disease with perianal fistula.1
New subgroup analyses show consistent outcomes across key patient subgroups
Expanding on previously reported results in the overall population, new prespecified subgroup analyses showed greater Week 24 combined fistula remission with TREMFYA versus placebo among:1
Patients with greater luminal disease activity at baseline (CDAI ≥220): 30% and 21% with TREMFYA 100 mg SC q8w and 200 mg SC q4w, respectively, versus 0% with placebo Patients with prior biologic exposure: 21% and 29%, respectively, versus 5% with placebo Patients with proctitis at baseline: 26% and 27%, respectively, versus 12% with placebo Patients without proctitis at baseline: 29% and 27%, respectively, versus 10% with placebo Adverse events were consistent with the known safety profile of TREMFYA in Crohn's disease.1
"Perianal fistula remain one of the most debilitating manifestations of moderate to severe Crohn's disease and many patients continue to experience persistent drainage, pain and complications," said Bruce Sands, MD, MS, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine, and Chief, Division of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Health System. "These subgroup analyses show that the outcomes observed with TREMFYA were consistent across clinically important patient populations, further strengthening the evidence supporting its use in this difficult to treat patient population."
Addressing an important need in Crohn's disease
Perianal fistula affects nearly 25% of patients with Crohn's disease and is a severe, often debilitating manifestation associated with pain, persistent drainage, recurrent abscesses and a frequent need for surgical intervention.2 3 FUZION is a dedicated randomized, placebo-controlled Phase 3 study designed to evaluate TREMFYA in adults with Crohn's disease with perianal fistula.
"Johnson & Johnson has a longstanding commitment to advancing the science of inflammatory bowel disease, including for patients living with some of its most complex manifestations," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "FUZION was designed to generate rigorous evidence specifically in Crohn's disease with perianal fistula, helping us deepen our understanding of how TREMFYA can address an area of unmet need."
TREMFYA is the only approved dual-acting monoclonal antibody in inflammatory bowel disease (IBD) that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC. Findings are based on in vitro studies.45678
Dr. Bruce Sands is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
For a full list of all Johnson & Johnson data being presented at ACG visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.
Editor's notes:
a. Combined fistula remission was defined as complete closure of all external fistula openings with no drainage, without development of new fistulas, and absence of underlying fluid collections on MRI.
About the FUZION study (NCT05347095)
FUZION is a randomized, placebo-controlled, double-blind, multicenter, Phase 3 study designed to evaluate the efficacy and safety of TREMFYA in adults with Crohn's disease with perianal fistula. Patients enrolled in the study had one or more active draining perianal fistulas confirmed by blinded central MRI review, CD Activity Index [CDAI] <350, and inadequate response to oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or up to 2 advanced therapy classes. Patients were randomized 2:2:1 to receive TREMFYA 200 mg intravenous (IV) induction at Weeks 0, 4, 8 weeks followed by TREMFYA 100 mg subcutaneous (SC) induction every 8 weeks (q8w); or TREMFYA 200 mg IV infusion in at Weeks 0, 4, 8 weeks followed by TREMFYA 200 mg SC every 4 weeks (q4w); or placebo.9
About Crohn's disease
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.1011 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.12 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Some patients may also develop fistulas, abnormal connections between the intestine and other organs or tissues, which can be associated with pain, drainage, infection, and substantial impairment in quality of life. Currently no cure is available for Crohn's disease.13
About TREMFYA (guselkumab)
Developed by Johnson & Johnson, TREMFYA is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate TREMFYA binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA is a prescription medicine approved in the U.S. to treat:
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis. adults with moderately to severely active ulcerative colitis. adults with moderately to severely active Crohn's disease. TREMFYA is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.
The manufacturer for TREMFYA is Janssen Biotech, Inc.
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA. For more information, visit: www.tremfya.com.
TREMFYA IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA?
TREMFYA is a prescription medicine that may cause serious side effects, including:
Serious Allergic Reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
o fainting, dizziness, feeling lightheaded (low blood pressure)
o swelling of your face, eyelids, lips, mouth, tongue or throat
o trouble breathing or throat tightness
o chest tightness
o skin rash, hives
o itching
Infections. TREMFYA may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
o fever, sweats, or chills
o muscle aches
o weight loss
o cough
o warm, red, or painful skin or sores on your body different from your psoriasis
o diarrhea or stomach pain
o shortness of breath
o blood in your phlegm (mucus)
o burning when you urinate or urinating more often than normal
Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA. Your healthcare provider may stop treatment with TREMFYA if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
o unexplained rash
o vomiting
o tiredness (fatigue)
o yellowing of the skin or the whites of your eyes
o nausea
o stomach pain (abdominal)
o loss of appetite
o dark urine
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA. are pregnant or plan to become pregnant. It is not known if TREMFYA can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA during pregnancy. are breastfeeding or plan to breastfeed. It is not known if TREMFYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects. See "What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects.
Use TREMFYA exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com
Follow us at @JNJInnovMed.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
REFERENCES
________________________________________________
1 Bruce E. Sands, Alisa Hart, et al Efficacy of Guselkumab in Perianal Fistulizing Crohn's Disease: Week 24 Results From The Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study. P5691 at ACG Annual Scientific Meeting 2026. October 13 2026
2 Sulak A., et al. Where Are We and Where to Next?—The Future of Perianal Crohn's Disease Management, Journal of Clinical Medicine, Volume 12, Issue 19, October 2023, 6379, https://doi.org/10.3390/jcm12196379.
3 Spinelli A, Yanai H, Girardi P, Milicevic S, Carvello M, Maroli A, Avedano L. The Impact of Crohn's Perianal Fistula on Quality of Life: Results of an International Patient Survey. Crohns Colitis 360. 2023 Jul 25;5(3):otad036. doi: 10.1093/crocol/otad036. PMID: 37529012; PMCID: PMC10390083.
4 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn's and Colitis Organization (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504.
5 Kreuger JG, Eyerich K, Kuchroo VK. Il-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024; 15:1331217. doi:10.3389/fimmu.2024.1331217.
6 TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
7 Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie, Inc.
8 Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
9 National Institutes of Health: Clinicaltrials.gov. A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD). Identifier: NCT05347095. https://clinicaltrials.gov/study/NCT05347095?tab=researcher. Accessed March 2026.
10 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed August 2026.
11 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
12 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed August 2026.
13 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed August 2026.
Společnost Johnson & Johnson uvedla, že ve studiích GALAXI 2 a GALAXI 3 dosáhlo po třech letech klinické remise až 94 % pacientů s Crohnovou nemocí léčených přípravkem TREMFYA.
New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease
88% of patients achieved 90-day corticosteroid-free clinical remission
, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease.1 The Week 144 long-term extension (LTE) results being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting reveal long-term clinical and endoscopic outcomes across both TREMFYA maintenance regimens in this chronic disease.
Clinical and endoscopic outcomes sustained through three years with TREMFYA
Patients in the GALAXI 2 and 3 studies received intravenous induction followed by one of two TREMFYA maintenance dosing regimens: 100 mg administered subcutaneously every eight weeks (q8w) or 200 mg administered subcutaneously every four weeks (q4w). At Week 144 the LTE data show:1a
94% of patients receiving TREMFYA 100 mg q8w and 91% receiving TREMFYA 200 mg q4w achieved clinical remission.b
88% of patients receiving TREMFYA 100 mg q8w and 88% receiving TREMFYA 200 mg q4w achieved 90-day corticosteroid-free clinical remission, respectively.
52% of patients receiving TREMFYA 100 mg q8w and 61% receiving TREMFYA 200 mg q4w achieved endoscopic remission.c
74% of TREMFYA-treated patients remained on treatment through three years.
Safety findings through Week 144 were consistent with the well-established safety profile of TREMFYA in Crohn's disease.1
"In a chronic, lifelong disease, the ability to sustain clinical and endoscopic outcomes through three years is particularly meaningful for patients," said David Rubin, MD, Director of the Inflammatory Bowel Disease Center at the University of Chicago.d "These results contribute to the growing body of evidence that TREMFYA can provide patients with deep and sustained remission over time, creating a strong foundation for long-term disease management."
Long-term disease control is an important need in Crohn's disease management
As Crohn's disease is a lifelong disease with no cure, patients and physicians need treatments that can provide sustained control of symptoms and intestinal inflammation over time. These results represent one of the most comprehensive three-year datasets in Crohn's disease reported to date, demonstrating durable clinical, corticosteroid-free and endoscopic remission across both TREMFYA maintenance regimens.
"Johnson & Johnson has built deep expertise in immune-mediated diseases including inflammatory bowel disease, and our research is designed to answer questions that arise over the course of this chronic condition," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "The clinical and endoscopic remission observed with TREMFYA through three years reinforces our commitment to generating long-term evidence that can help physicians make informed treatment decisions for people living with Crohn's disease."
TREMFYA is the only approved dual-acting monoclonal antibody in inflammatory bowel disease (IBD) that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC. Findings are based on in vitro studies.2 3 4 5 6
For a full list of all Johnson & Johnson data being presented at ACG visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.
Editor's notes:
a. The Week 144 clinical remission, 90-day corticosteroid-free clinical remission and endoscopic remission results above represent the as observed data for the three-year GALAXI analysis. The observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 144; participants who had a dose adjustment were not include
b. Clinical remission was defined as a CDAI score <150.
c. Endoscopic remission was defined as an SES-CD ≤4, with a ≥2-point reduction and no subscore >1 on any subcomponent.
d. Dr. David Rubin is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
About the GALAXI program (NCT03466411)
GALAXI is a randomized, double-blind, placebo-controlled, active-controlled (ustekinumab), global, multicenter Phase 2/3 program designed to evaluate the efficacy and safety of TREMFYA in participants with moderately to severely active Crohn's disease with inadequate response/intolerance to conventional therapies (corticosteroids or immunomodulators) and/or biologics (TNF antagonists or vedolizumab). GALAXI includes a Phase 2 dose-ranging study (GALAXI 1) and two independent, identically designed confirmatory Phase 3 studies (GALAXI 2 and 3). Each GALAXI study employed a treat-through design and includes a long-term extension period that will assess clinical, endoscopic, and safety outcomes with TREMFYA treatment through a total of five years. Patients received TREMFYA 200 mg intravenous induction at Weeks 0, 4 and 8 followed by TREMFYA 200 mg subcutaneous maintenance every 4 weeks; or TREMFYA 200 mg intravenous induction at Weeks 0, 4 and 8, followed by TREMFYA7
About Crohn's disease
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.89 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.10 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Some patients may also develop fistulas, abnormal connections between the intestine and other organs or tissues, which can be associated with pain, drainage, infection, and substantial impairment in quality of life. Currently no cure is available for Crohn's disease.11
About TREMFYA (guselkumab)
Developed by Johnson & Johnson, TREMFYA is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate TREMFYA binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA is a prescription medicine approved in the U.S. to treat:
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis.
adults with moderately to severely active ulcerative colitis.
adults with moderately to severely active Crohn's disease.
TREMFYA is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.
The manufacturer for TREMFYA is Janssen Biotech, Inc.
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA. For more information, visit: www.tremfya.com.
TREMFYA IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA?
TREMFYA is a prescription medicine that may cause serious side effects, including:
Serious Allergic Reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
o fainting, dizziness, feeling lightheaded (low blood pressure)
o swelling of your face, eyelids, lips, mouth, tongue or throat
o trouble breathing or throat tightness
o chest tightness
o skin rash, hives
o itching
Infections. TREMFYA may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
o fever, sweats, or chills
o muscle aches
o weight loss
o cough
o warm, red, or painful skin or sores on your body different from your psoriasis
o diarrhea or stomach pain
o shortness of breath
o blood in your phlegm (mucus)
o burning when you urinate or urinating more often than normal
Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA. Your healthcare provider may stop treatment with TREMFYA if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
o unexplained rash
o vomiting
o tiredness (fatigue)
o yellowing of the skin or the whites of your eyes
o nausea
o stomach pain (abdominal)
o loss of appetite
o dark urine
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA?"
have an infection that does not go away or that keeps coming back.
have TB or have been in close contact with someone with TB.
have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA.
are pregnant or plan to become pregnant. It is not known if TREMFYA can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA during pregnancy.
are breastfeeding or plan to breastfeed. It is not known if TREMFYA passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects. See "What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects.
Use TREMFYA exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com
Follow us at @JNJInnovMed.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
REFERENCES
____________________________
1 D'Haens GR, Rubin DT, et al. Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn's Disease: Phase 3 Long-term Extension Data From GALAXI 2 and GALAXI 3 P5693 at ACG Annual Scientific Meeting 2026. October 13 2026.
2 Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an IL-23p19 subunit-specific monoclonal antibody, binds CD64+ myeloid cells and potentially neutralizes IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn's and Colitis Organization (ECCO); March 1-4, 2023; Copenhagen, Denmark. Poster P504.
3 Kreuger JG, Eyerich K, Kuchroo VK. Il-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024; 15:1331217. doi:10.3389/fimmu.2024.1331217.
4 TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
5 Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie, Inc.
6 Omvoh™ [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
7 Panaccione, R et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the GALAXI 2 & 3 phase 3 studies. Oral presentation (Abstract #1057b) at Digestive Disease Week (DDW) 2024. May 2024.
8 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed August 2026.
9 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
10 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed August 2026.
11 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed August 2026.
FUNToken has announced the addition of ENA to its growing list of supported tokens, further strengthening its commitment to improving token accessibility and simplifying participation across its ecosystem.
With this latest integration, users holding ENA can now deposit their tokens directly into the FUNToken platform, where they are automatically converted into $FUN with 0% conversion fees. The process eliminates the need for manual token swaps, offering users a straightforward way to access $FUN and explore its expanding range of utilities.
Making $FUN More Accessible Through Token Integration Table of Contents
As the digital asset landscape continues to evolve, users increasingly hold multiple tokens across different networks. FUNToken aims to simplify the experience of accessing its ecosystem by supporting a growing selection of tokens that can be converted into $FUN.
The addition of ENA (ERC-20) introduces another option for users looking to put their existing digital assets to use without navigating multiple conversion platforms.
Through FUNToken’s automatic conversion system, ENA holders can deposit their tokens and receive $FUN without incurring additional conversion fees.
This streamlined approach is part of FUNToken’s broader effort to reduce unnecessary steps, improve accessibility, and create a more connected experience for its users.
Expanding Utility Beyond Token Conversion The integration of ENA goes beyond simply adding another supported asset. It creates an additional entry point into FUNToken’s growing ecosystem of gaming experiences, staking opportunities, and token-based rewards.
Once ENA is converted into $FUN, users can explore the different utilities available within the ecosystem.
FUNToken’s expanding Android gaming portfolio features nine titles designed around accessible, engaging gameplay, with no ads, no paywalls, and real $FUN rewards. The ecosystem also includes browser-based gaming experiences, staking features, and referral reward opportunities.
By connecting these experiences through a common token, FUNToken continues to build an environment where $FUN serves multiple purposes across different products and activities.
A Growing List of Supported Tokens The addition of ENA reflects FUNToken’s ongoing strategy to expand the range of digital assets supported by its automatic conversion system.
Recent integrations have included ONDO, TRUMP, FARTCOIN, and JTO, alongside previously supported tokens such as USDT, USDC, SOL, LINK, UNI, AAVE, and others.
Each new integration provides users with additional flexibility in accessing $FUN while supporting the platform’s objective of making token conversion more convenient.
With 0% conversion fees remaining a central feature of the supported token system, FUNToken continues to focus on simplifying the transition from existing token holdings into its connected gaming and rewards ecosystem.
Continuing to Build a More Connected $FUN Ecosystem The ENA integration represents another step in FUNToken’s ongoing ecosystem expansion.
Alongside its growing supported token list, FUNToken continues to develop new gaming experiences, expand token utility, and introduce additional opportunities for users to participate.
By combining accessible token conversion with an expanding range of products, FUNToken is working toward an ecosystem where users have greater flexibility in how they access, earn, hold, and use $FUN.
As further integrations and platform developments are introduced, the project remains focused on making participation simpler and creating more practical uses for $FUN.
About FUNToken FUNToken is a blockchain-powered ecosystem built around $FUN, combining gaming, rewards, staking, and growing token utility within a connected experience.
With an expanding portfolio of Android and browser-based games, supported token integrations, multi-chain accessibility, and reward opportunities, FUNToken is focused on creating more ways for users to access, earn, hold, and use $FUN.
The ecosystem emphasizes accessible gaming experiences, including a growing selection of Android titles featuring no ads, no paywalls, and $FUN rewards.
Through continued product development and ecosystem expansion, FUNToken aims to strengthen the role of $FUN as a common token connecting its growing range of digital experiences.
Website: https://funtoken.io
Disclaimer: This is a Press Release provided by a third party who is responsible for the content. Please conduct your own research before taking any action based on the content.
Disney jmenoval Karandeepa Ananda prvním CTO pro celou společnost, který povede technologickou transformaci s cílem lépe konkurovat Netflixu a YouTube ve streamingu.
You're currently following this author!
Click to unsubscribe from email alerts.
Disney hired Karandeep Anand from Character.AI to oversee its technology strategy.
Manaure Quintero / AFP via Getty Images; Illustration by Samuel Boivin/NurPhoto via Getty Images
Disney's new tech chief said in a memo to employees that he "won't pretend it will be easy" to win in the changing media environment.
Karandeep Anand, the Mouse House's first-ever companywide CTO, was hired by CEO Josh D'Amaro to lead Disney's tech transformation. He started in early October. Under D'Amaro, Disney is investing in tech to better compete with Netflix and YouTube in streaming.
Anand previously ran Character.AI, an AI startup that Disney sent a cease-and-desist letter to last fall. (Disney told Character.AI not to make chatbots from its copyrighted characters without permission, and the startup complied.)
Anand told staffers on Friday afternoon that the media business is "at an inflection point," adding that he's confident Disney has a strong hand thanks to its deep, iconic content library and a passionate fan base.
"With our rich IP and global fan community, I strongly believe we are uniquely positioned to win," Anand said in his memo, which was obtained by Business Insider.
The new tech chief said that winning in this highly competitive media landscape "will take focus, speed, and the willingness to say no to good ideas so we can say yes to great ones."
Anand also said he's "admired Disney for as long as I can remember" and said he had constructive conversations in his first full week inside the Mouse House.
"What stands out most is the talent and care this team puts into its work, the craft Disney has perfected, and the strong foundation you've built," Anand said.
Disney has leaned into tech this year by embracing AI and further unifying Disney+ and Hulu — the first step in building a streaming super app that includes games and merchandise.
Anand highlighted the same three top priorities that D'Amaro listed in the memo announcing his hire: great storytelling as our North Star, technology in service of creativity, and operating as One Disney.
D'Amaro is contending with Disney's listless stock price. Shares have fallen more than 1% in the past year, compared to a 17.3% gain for the S&P 500, and are down over 38% in the past five years, while US stocks broadly have risen more than 74%.
Read Anand's full memo below:
Team,As I close out my first week at Disney, thank you for the warm welcome you gave me and the colleagues who joined me.I've admired Disney for as long as I can remember, so walking the lot, attending the Tech Showcase, and meeting so many of you has been an unforgettable start. What stands out most is the talent and care this team puts into its work, the craft Disney has perfected, and the strong foundation you've built.It's only been a few days, but I'm more excited than when I accepted this job. Josh has laid out three priorities: great storytelling as our North Star, technology in service of creativity, and operating as One Disney. Our job in technology is to make those real, and the possibilities are enormous. We're at an inflection point in the tech and media industry, and with our rich IP and global fan community, I strongly believe we are uniquely positioned to win.I won't pretend it will be easy. It will take focus, speed, and the willingness to say no to good ideas so we can say yes to great ones. I'll be direct with you about priorities and tradeoffs as I learn them. But I'm confident we can get there, and do it quickly.Over the coming weeks I'll be meeting with teams across the company, and I look forward to sharing how I'm thinking about our priorities soon. Until then, please keep doing the great work you're doing.Thank you again. I'm glad and privileged to be on this team.Karan
Read next
James Faris
You're currently following this author!
Click to unsubscribe from email alerts.
James Faris is a media correspondent in New York City.He covers the business of media & entertainment, specifically the streaming, TV, and AI strategies of Hollywood giants like Disney, Skydance (Paramount-WBD), and Netflix. He previously wrote about the stock market, the economy, and real estate.James joined Business Insider after graduating magna cum laude from James Madison University.Email James at [email protected] and follow him on LinkedIn.
GE Aerospace, Shield AI a WZL-2 podepsaly memorandum o porozumění, které prověří možnosti údržby, oprav a generálních oprav motorů F110 pro autonomní letoun X-BAT v Polsku; očekávané tržby nezveřejnily.
The next frontier of artificial intelligence may not be another data center, but a fighter aircraft that can operate without a runway. GE Aerospace (NYSE:GE) is positioning its engine technology alongside Shield AI’s autonomous aircraft ambitions, creating a potential new defense opportunity as militaries explore ways to deploy AI-powered airpower beyond traditional infrastructure.
• GE Aerospace stock is holding steady today. What’s the outlook for GE shares?
GE Enters the Autonomous Fighter PushOn Oct. 12, GE Aerospace, Shield AI and Poland’s Wojskowe Zakłady Lotnicze Nr 2 (WZL-2) signed a memorandum of understanding to explore maintenance, repair and overhaul capabilities in Poland for GE’s F110 engine powering Shield AI’s X-BAT aircraft.
The announcement covers the engine and its Axisymmetric Vectoring Exhaust Nozzle, which enables thrust vectoring for vertical takeoff and landing. The companies will assess the facilities, equipment and training needed to establish local maintenance capabilities.
X-BAT is designed to take off and land vertically, potentially allowing it to operate from roads, ships and smaller sites instead of conventional runways. That flexibility could matter on NATO’s eastern flank, where airfields could be vulnerable during a conflict.
Shield AI brings the autonomous flight technology; GE supplies the propulsion system and engine-support expertise. GE is not developing the aircraft’s AI pilot, but its technology is part of the physical infrastructure needed to make the aircraft operational.
Read Next
The AI Opportunity Beyond Data CentersFor GE investors, the potential opportunity lies in the hardware and services behind autonomous systems. AI-enabled aircraft still require propulsion, specialized components, repairs and maintenance — areas where established aerospace suppliers could benefit if new platforms progress from development to deployment.
GE’s F110 engine has accumulated more than 11 million flight hours over four decades of continuous production and improvement, according to the company. Its experience gives GE an established role in the program, while the thrust-vectoring nozzle is designed to support X-BAT’s vertical flight capability.
The partnership also builds on a September letter of intent involving Shield AI, Poland’s state-owned defense group PGZ and WZL-2 to explore X-BAT design, production and delivery in Poland. The latest agreement extends that ambition to potential in-country engine support.
What It Means for GE StockThe distinction between strategic positioning and financial impact remains important. The memorandum is an agreement to explore maintenance capabilities, not a confirmed engine order or a guarantee that a Polish facility will be established. The companies have not disclosed expected revenue from the arrangement.
For GE, the opportunity depends on X-BAT advancing toward deployment and generating demand for engines, repairs and long-term sustainment. Investors should watch for firm contracts, production milestones and evidence that the program can translate into incremental business.
Investment takeaway: Shield AI is giving GE Aerospace a potential role in the infrastructure behind autonomous warfare, extending its exposure to AI beyond the data center boom. But until the partnership produces firm orders or measurable revenue, it remains a strategic opportunity rather than a material earnings catalyst.
Read Next
Photo: Officials from the companies sign the MOU, Photo courtesy GE Aerospace
The latest quote sits approximately 1.2% below Stephen Rusckowski's disclosed September entry. Summary
Insider buying supplies conviction, but Oracle’s infrastructure returns still require operating evidence.
Oracle ORCL, the enterprise-software and AI-cloud provider, trades at $137.745, down about 2.6% at 12.34pm EST on October 12 and roughly 1.2% below a director's recent purchase price. A nearly $3.5 million insider investment adds conviction to the story. It does not settle the bigger question: how much cash Oracle's AI infrastructure push will ultimately generate.
An October 1 SEC filing shows that director Stephen Rusckowski's living trust bought 25,000 shares on September 29 at a weighted average of $139.352. That works out to $3,483,800 based on the reported average. Barron's describes the transaction as his first open-market purchase since joining Oracle's board. The valuation snapshot places shares 29.51% below the $195.40 GF Value estimate, suggesting potential upside if the business delivers on those expectations.
That discount deserves attention. So does the execution risk. A director's purchase offers a vote of confidence, while a valuation estimate offers a benchmark; neither guarantees a return. Investors still need to watch infrastructure utilization, customer payments and the cash earned against the money spent building capacity. Oracle's next test is turning AI demand into durable cash flow.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
The 10-year U.S. Treasury note rarely looks this appealing. Its yield reached 5.22% on Oct. 8, according to Federal Reserve data, the highest reading since March 2002. Costco Wholesale (COST +1.32%) offers a forward dividend yield of 0.6%.
Put $10,000 into each, and the Treasury hands you payouts of about $520 a year while Costco sends you around $60. Why bother?
But income is only one piece of an investment's return, and for long-term investors, it's often a small part.
Premium Feature
Moneyball Superscore
83/100
Today's Change
(
1.32
%) $
12.52
Current Price
$
959.44
The hot dog doesn't get bigger Like Costco's famous hot dog and soda combo (still $1.50 after 41 years), Treasury coupons have a fixed value. A 10-year note's coupon rate is locked for 10 years. The interest you receive in 2036 will match next spring's payment to the penny, even after a decade of inflation.
Hold to maturity, and you get your original $10,000 back; it'll just buy less stuff than it does today. The coupon payouts you receive along the way will help, assuming the rate you locked in remains ahead of average inflation.
Rate changes only matter if you sell your Treasuries before maturity. No one will pay full price for your note if new Treasuries offer better rates, but your note will gain value when rates go down.
But Costco's dividend has grown 13.2% per year over the last five years. The company also has a habit of surprising shareholders with special dividends, such as the $15-per-share dividend it paid in January 2024. That one-time payment was roughly equivalent to 15 of the regular quarterly payouts at the time.
The business behind the stock Stocks let you own a small piece of an actual business. People work hard to increase the corporation's value, which over time lifts the stock price. No empire lasts forever, but Costco's story started decades ago, and it's still a market-beating growth stock.
Costco generated $303.2 billion in sales over the past 12 months, up 10.1% year over year. Earnings per share rose 13.9% over the same period. The company keeps markups low, with a gross margin of just 12.8%, and earns a large share of its operating profit from membership fees.
As a result, $10,000 invested in Costco stock 10 years ago would be worth $63,340 today. With reinvested dividends, you're looking at $74,980 instead:
COST data by YCharts
10-year Treasury notes yielded about 1.8% in October 2016. A $10,000 investment would pay out $11,800 in total over the same decade. That's your original $10,000 plus $1,800 in coupon payouts. Treasuries bought today will pay out roughly $5,200 over the next 10 years (plus the $10,000 return of principal), but that's still a forgettable gain next to Costco's long-term returns.
The catch Costco's stock isn't cheap, exposing investors to valuation risk. It trades at 46 times trailing earnings and 38.2 times forward estimates, which is a rich price for a company expected to grow earnings about 9.7% annually.
The stock gained just 2.8% over the past year, trailing the Treasury's yield, and sits 12.8% below its 52-week high as of Oct. 12.
Image source: The Motley Fool.
Pick your cart If you need reliable income soon, the Treasury is a fine choice at 5.2%. But if you don't need the money for the next 10 years, Costco offers a few things that the Treasury note can't: a business that keeps growing, a dividend that keeps rising, and a long record of turning patient money into a much bigger pile.
Morgan Stanley označila eBay za svůj hlavní tip, zvýšila cílovou cenu akcií na 132 USD a očekává, že živé prodeje budou představovat více než 40 % růstu společnosti.
Morgan Stanley sees live selling driving more than 40% of eBay's growth Summary
Morgan Stanley named eBay a top pick, raised its target to $132 from $127 and kept Overweight, citing live selling as an underappreciated growth engine.
eBay EBAY rose 3.50% as of 1:00 p.m. ET after Morgan Stanley named it a top pick and raised its price target to $132 from $127, keeping an Overweight rating. Analyst Nathan Feather said eBay's acceleration in gross merchandise volume had come as a surprise, and argued that live selling is a bigger growth engine than the Street has appreciated.
Morgan Stanley estimated that live selling could account for more than 40% of eBay's growth, and forecast compound annual growth of about 22% for that business through 2030. The call builds on what eBay reported in August. Second-quarter GMV rose 15% on an as-reported basis to $22.4 billion, and GMV on eBay Live grew roughly eightfold year over year across its seven markets.
On the other hand, Wells Fargo cut its target to $91 from $92 and kept an Underweight rating, warning that investment in live selling and competition could weigh on earnings growth.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Barclays zahájila analytické pokrytí společnosti Palantir s doporučením „nadvážit“ a cílovou cenou 265 USD, což představuje přibližně 27,7% růstový potenciál.
Barclays' objective implies approximately 27.7% upside, versus 10.9% for Goldman Sachs' $230 target.
Summary
Analyst enthusiasm varies materially while Palantir’s revenue remains heavily concentrated in the United States.
Palantir Technologies PLTR, the enterprise and government AI-software company, draws bullish analyst attention, but shares slipped about 1.1% to $206.90 at 12.20pm EST. Wall Street's targets leave plenty of room for disagreement. Barclays' $265 objective implies roughly 28% upside from that price. Goldman's $230 target puts the potential gain closer to 11%. Neither is a promise.
Yahoo Finance reported that Barclays initiated coverage with an Overweight rating and the $265 target. The operating numbers explain the focus on U.S. demand: second-quarter U.S. commercial revenue reached $764 million, while U.S. government revenue totaled $809 million. Together, those businesses generated about 81.3% of approximately $1.935 billion in companywide revenue. That concentration gives investors two engines to watch: corporate adoption and government spending.
The valuation snapshot puts shares 11.28% above the $185.92 GF Value estimate, suggesting the price already carries a premium to that benchmark. Palantir still has to earn that premium. More contracts help, but the stronger test is whether deployments produce recurring revenue without engineering costs climbing just as quickly. Expanding sovereign demand could widen the opportunity. Turning that demand into repeatable, profitable growth is what makes the bullish targets credible.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
GameStop Corp. (NYSE:GME) shares are rising Monday to a fresh 52-week high. Here’s what you need to know.
GameStop shares are testing new highs. What’s behind GME new highs?
Monday’s trading range of $26.82 to $27.02 clears the old 52-week high of $26.88, set May 1. Over the past year, GameStop has ranged from a low of $17.79. The stock has gained around 27%.
Insider Buying Keeps Investors Interested in GameStopOn Thursday, October 8, GameStop jumped more than 4% while investors digested a run of insider purchases and eyed a looming warrant deadline. The Nasdaq lost 1.59% and the S&P 500 dropped 0.67% that day, so GameStop outpaced the market.
CEO Ryan Cohen spent about $17.1 million on 700,000 shares on October 2, after making several multimillion-dollar purchases in September. Nat Turner, a director, picked up 10,462 shares on October 1, and Lawrence Cheng, another director, bought 55,000 shares in September. Such buying can reflect management’s faith in the company’s long-term path, but it offers no guarantee of future gains.
In October 2025, GameStop issued warrants to eligible shareholders, one per 10 shares owned on the record date. Each warrant gives its holder the right to buy a common share at $32 until it expires October 30. With the stock still under $32, using a warrant costs more than simply buying shares in the market. Warrants still unused on October 30 become worthless, and the nearing cutoff could pull in more trading.
GameStop Stock Presses Into Key ResistanceThe stock last changed hands just below the $27.00 resistance level, with support sitting at $22.50. The rally followed a slide from the May 1 high to the August 20 low of $17.79.
Monday’s gain places shares over their 20-day average of $24.13, 50-day average of $20.98 and 200-day average of $22.36. The 20-day line sits above the 50-day, but the 50-day still trails the 200-day. That combination signals firmer short-term momentum inside a longer-term downtrend.
GME Shares Are ClimbingGME Price Action: GameStop shares were up 1.05% at $26.84 at the time of publication on Monday. The stock is trading near its 52-week high of $26.88, according to Benzinga Pro.
Read Next
Image: JRdes/Shutterstock
Market News and Data brought to you by Benzinga APIs
Podíl společnosti ADM na zisku společnosti Wilmar International klesl ve druhém čtvrtletí 2026 meziročně o 22 % na 60 milionů USD, a to navzdory téměř 5% růstu globálního zpracování olejnin.
Key Takeaways ADM's equity earnings from Wilmar fell 22% to $60 million in Q2 2026 from $77 million a year ago.Stronger oilseed profits and nearly 5% growth in global processing volumes failed to offset Wilmar's weakness.Commodity price swings, margin pressures and rising costs could continue to weigh on Wilmar's earnings. Archer Daniels Midland Company (ADM - Free Report) has been facing pressure from its investment in Wilmar International for a while now. The company reported a 22% year-over-year decline in equity earnings from its investment in Wilmar International to $60 million in the second quarter of 2026 compared with $77 million in the prior-year quarter. The decline raises questions about the sustainability of earnings from this investment, even as ADM delivered strong overall quarterly results.
Wilmar International, a Singapore-based agribusiness company, operates across palm oil, edible oils, oilseeds, grains, sugar and food products. Its earnings are sensitive to fluctuations in commodity prices, processing margins, demand trends and operating costs. Changes in these factors can influence Wilmar’s profitability and, in turn, the equity earnings ADM receives from its investment.
Notably, ADM's broader business benefited from favorable market conditions during the quarter. The company's Ag Services and Oilseeds segment recorded higher operating profits, supported by improved commercial execution, stronger South American performance and favorable biofuel-related crushing margins. Global oilseed processing volumes increased nearly 5% year over year. However, these positive developments did not prevent Wilmar's earnings from declining.
The decline in Wilmar’s earnings could indicate pressure on margins or unfavorable conditions across certain agricultural commodity markets. Fluctuations in raw material prices, changes in demand for food products and shifts in global trade flows can influence processing volumes and profitability.
For ADM, Wilmar’s earnings trajectory remains an important factor in evaluating the investment’s contribution to overall results. Investors should monitor Wilmar’s earnings, commodity price trends and processing margins to gauge the outlook for this investment. An improvement in Wilmar’s profitability could boost ADM’s equity earnings, while persistent weakness may limit the contribution despite stronger performance in other business segments. Until a sustained recovery becomes evident, subdued earnings from Wilmar could remain a headwind for ADM’s overall earnings outlook.
ADM’s PeersDole plc (DOLE - Free Report) is benefiting from steady demand for fresh produce, disciplined pricing strategies and improved operational efficiency. DOLE is strengthening its vertically integrated supply chain through investments in farming operations, packing facilities, ripening centers and logistics infrastructure. These initiatives are supporting cost efficiencies, enhancing product quality and improving supply reliability. Dole is also expanding its presence in high-growth categories, such as cherries and citrus, by increasing production capacity and modernizing packing facilities to meet rising customer demand and capture additional growth opportunities.
Adecoagro S.A. (AGRO - Free Report) is a leading South American agribusiness and renewable energy company with a growing presence across agricultural and consumer markets. AGRO's ability to adjust the production mix between sugar and ethanol in response to changing market conditions provides operational flexibility and helps optimize profitability. Adecoagro is also adopting digital technologies, renewable energy solutions and precision agriculture practices to improve productivity, streamline operations and manage costs more effectively.
ADM’s Price Performance, Valuation and EstimatesArcher Daniels shares have gained 16.2% in the past six months compared with the industry’s 0.4% drop.
Image Source: Zacks Investment Research
From a valuation standpoint, ADM trades at a forward price-to-earnings ratio of 14.29X compared with the industry’s average of 11.67X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADM’s 2026 and 2027 earnings per share (EPS) indicates year-over-year growth of 58.9% and 3.4%, respectively. The company’s EPS estimate for 2026 and 2027 has increased in the past 30 days.
Image Source: Zacks Investment Research
Archer Daniels currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Key Takeaways Fortinet's non-GAAP operating margin hit a record 38% in Q2 2026, while free cash flow reached $966M.Fortinet raised 2026 operating margin guidance to 35-37% and non-GAAP EPS guidance to $3.41-$3.47.FTNT's 33.7% GAAP operating margin outpaced CRWD's, despite product-mix pressure and rising memory chip costs.
Fortinet (FTNT - Free Report) is sharpening its AI security push, and the effort increasingly reinforces its margin narrative. In August, the company acquired Virtue AI, which adds runtime protection and automated validation for AI models, applications and autonomous agents to complement FortiAIGate. Fortinet said the amount paid was immaterial. In September, Fortinet was named a Leader in the 2026 Gartner Magic Quadrant for Hybrid Mesh Firewall. These moves build on the FortiGate 1200G with FortiSASE Outpost, which targets AI infrastructure requirements, and an Intel collaboration on its SP6 security processor.
Second-quarter 2026 results showed this momentum turning into profitability. Non-GAAP operating margin expanded to a record 38% from 33.1% a year ago, and GAAP operating margin rose to 33.7% from 28.1%. Product gross margin improved 2.4 percentage points to 69.8%, helped by recent pricing actions. Free cash flow reached $966 million, representing a 47.2% margin.
Guidance underlines the margin strength. For 2026, Fortinet now expects a non-GAAP operating margin of 35-37%, up from the earlier guidance of 33-36%, and a non-GAAP gross margin of 79-81%. Revenues are projected to be in the range of $8.02-$8.18 billion, implying 19% growth. Service revenue is expected at $5.18-$5.22 billion and billings at $9.35-$9.55 billion. Non-GAAP EPS guidance was raised to $3.41-$3.47 from $3.10-$3.16. For the third quarter, Fortinet expects revenues of $2.01-$2.10 billion, non-GAAP operating margin of 35-37% and non-GAAP EPS of 83-87 cents.
However, challenges persist. Total GAAP gross margin slipped to 80.2% from 80.7% as the revenue mix shifted 6.5 percentage points toward lower-margin product revenues, while memory chip costs rose. Service gross margin dipped slightly on data center expansion costs. Third-quarter operating margin guidance also implies a step down from the second quarter’s record level.
Overall, raised guidance, robust cash generation and AI-driven product momentum keep Fortinet’s margin profile attractive. Product-mix pressure and rising component costs, however, warrant close monitoring in coming quarters.
How FTNT’s Margins Stack Up Against PANW and CRWDFortinet’s margin profile compares favorably with Palo Alto Networks (PANW - Free Report) and CrowdStrike (CRWD - Free Report) , though both rivals continue to expand their top lines rapidly. Palo Alto Networks’ fiscal fourth-quarter 2026 revenues rose 34% to $3.41 billion, with non-GAAP operating income of $1.01 billion, implying a margin near 30%. For fiscal 2027, Palo Alto Networks expects a 29.5% non-GAAP operating margin and a 38% adjusted free cash flow margin. CrowdStrike’s second-quarter fiscal 2027 revenues grew 26% to $1.47 billion, while non-GAAP operating margin improved to 25% from 22%. However, CrowdStrike still reported a negative 2% GAAP operating margin, well below Fortinet’s 33.7%.
FTNT’s Share Price Performance, Valuation & EstimatesFortinet shares have gained 144.7% in the year-to-date period, outperforming the Zacks Security industry and the broader Computer and Technology sector’s growth of 117.6% and 23.5%, respectively.
FTNT’s Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, FTNT appears overvalued, trading at a forward 12-month price-to-earnings ratio of 51.81, higher than the sector's average of 20.93. The company carries a Value Score of F.
FTNT’s Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Fortinet’s earnings is pegged at $3.45 per share for 2026, which implies year-over-year growth of 25%.
Fortinet currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Materials prohlubuje výzkumné partnerství se společností Intel v oblasti čipů pro AI, ale bez nových objednávek zařízení či zveřejněných finančních podmínek.
The research program spans logic and packaging, but neither company disclosed new equipment orders or project economics.
Summary
Earlier involvement in process development could help Applied win tools that eventually reach commercial production.
Applied Materials AMAT, the semiconductor equipment and materials-engineering supplier, deepens its AI-chip research partnership with Intel while shares trade at $499.70, down about 1.4% at 12.24pm EST on October 12. The opportunity is to help shape tomorrow's manufacturing tools before chipmakers lock in their production plans. But the collaboration comes without disclosed new equipment orders. More research access could strengthen Applied's position. It does not put revenue on the books today.
Applied's announcement outlines joint work on transistors, chip wiring and Foveros-based three-dimensional packaging across its Silicon Valley EPIC Center and Intel's Oregon research campus. EPIC is scheduled to be operationally ready this year. The commercial logic is straightforward: understanding Intel's process requirements earlier could help Applied focus its development spending on tools customers eventually buy. The release gives no development budget or commitments to specific commercial nodes, leaving the timing and size of any sales payoff uncertain.
The valuation leaves little room for disappointment: the stock sits 96.21% above its $254.67 GF Value estimate. That estimate is a reference point, not a ceiling, but it highlights how much optimism the price already carries. Applied still needs to turn laboratory progress into tools that qualify for production and generate repeat orders. Those milestones would give investors firmer evidence of a revenue opportunity. Until then, the Intel partnership strengthens the long-term case without establishing a near-term earnings boost.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Under the executable posted to the ENS forum, .eth sign-ups would pause for what Labs expects to be a few hours before reopening on ENSv2, and current names keep working with no action needed.
ENS Labs asks the DAO to switch on ENSv2
Posted October 12, 2026 at 12:18 pm ET.
ENS Labs has asked the ENS DAO to activate ENSv2 on Ethereum mainnet, a step that would freeze new .eth registrations on the original v1 registrar and move them to the new system.
ENS founder Nick Johnson, posting as nick.eth, published the executable proposal on the ENS governance forum on Oct. 11. It bundles 15 calls from the DAO timelock into a single atomic transaction. Those calls pull all five controllers now authorized on the v1 BaseRegistrar and add back just two: ETHRenewerV1, which handles renewals for names already reserved on v2, and a Graveyard contract that can claim names left expired past grace. Ownership of the registrar then passes to ETHRenewerV1, which, according to the post, can neither register new names nor add controllers. The post does not give a voting date, and no Tally or Snapshot vote had been linked as of publication.
Get Unchained’s crypto news in your inbox with the free Unchained Daily newsletter.
What It Means for .eth Holders
Existing owners don’t have to act. “If you own a .eth name and do nothing, it keeps working,” the post said, adding, “There’s no deadline to migrate.” Owners can move a name to v2 through the ENS app whenever they choose. Names that have lapsed past their grace period won’t carry over and will open up for anyone to register on v2.
ENSv2 shortens the post-expiry grace period to 28 days from 90. To compensate, “each name’s v2 expiry is extended by 62 days to make up the difference,” according to the proposal.
Registrations stop on both v1 and v2 between the proposal’s execution and v2 going live, a gap the post expects to last “a few hours.”
Labs Hands Over Control
Only one of the five activation stages requires a DAO vote. The last step, according to the proposal, is for ENS Labs to renounce its admin roles over the v2 contracts and pass them to the DAO timelock. Before that, Labs plans to re-run its name reservations after the freeze, let the v2 registrar take sign-ups and route name lookups through v2. Those steps are commitments by Labs, not part of the onchain vote. “When that’s done, the DAO controls ENSv2 just as it controls v1 today, and Labs holds no privileged role in either,” the post said. Registration fees on v2 are paid to the timelock, which has owned the fee-handling contracts since deployment.
The post also lists tradeoffs, including the loss of an emergency path on v1 that lets a designated controller disable a registrar controller without a vote. “The v1 freeze is reversible; migrating a name is not,” it said. The DAO could restore v1 controllers with another executable, but migrated tokens can’t be returned.
ENS Labs first pitched ENSv2 in 2024 as a move to a layer 2. The new proposal says the full v2 contract set is already deployed on Ethereum mainnet.
Related Listen: How One ENS Vote Reignited the DAO Governance Debate: Uneasy Money
AI-assisted content: This article was produced with the assistance of AI tools and was reviewed, edited, and fact-checked by a member of the Unchained editorial team before publication.
Key Takeaways PPL plans $23B in investments through 2029, targeting 10.3% average annual rate-base growth.
PPL targets 6-8% annual EPS growth through 2029 and 2026 EPS of $1.90-$1.98.
PPL raised its 2026 dividend by 4.6%, targeting 4-6% annual growth and a 50-60% payout ratio.
PPL Corporation (PPL - Free Report) aims to sustain shareholder returns through earnings growth and dividend increases while investing in regulated utility infrastructure.
The company’s capital allocation strategy centers on strengthening its regulated utility operations while expanding infrastructure to meet growing electricity demand. PPL plans infrastructure investments of $23 billion for the 2026-2029 period. These investments are expected to support average annual rate base growth of approximately 10.3% through 2029. It prioritizes modernizing transmission and distribution networks, improving grid reliability, and expanding generation and transmission infrastructure.
PPL raised its quarterly dividend by 4.6% in 2026 to an annualized $1.14 per share and continues to target 4-6% annual dividend growth through 2029, subject to board approval. The company also expects its dividend payout ratio to remain within 50-60% through the plan period.
PPL targets annual earnings per share (EPS) growth of 6-8% through at least 2029. Its 2026 ongoing EPS forecast remains $1.90-$1.98 per share, with a midpoint of $1.94. If infrastructure investments generate timely regulatory recovery and operating efficiencies, they could support earnings growth alongside rising dividends.
Overall, PPL’s capital allocation strategy offers a framework for combining infrastructure-led earnings growth with recurring shareholder distributions. Its success will depend on converting planned investments into earnings while managing financing needs and preserving balance-sheet strength.
Strategic Capital Allocation Drives Utility GrowthUtilities strategically allocate capital toward infrastructure upgrades, technology adoption and operational efficiency to strengthen financial performance. Disciplined investment decisions enhance asset utilization, support sustainable profitability and create long-term shareholder value. Apart from PPL, other utility companies are also benefiting from strategic capital allocation.
FirstEnergy Corp. (FE - Free Report) plans $36 billion in infrastructure investments through 2030, supporting regulated rate-base expansion, earnings growth, dividend sustainability and long-term shareholder value creation.
Edison International (EIX - Free Report) plans $38-$41 billion in capital investments through 2030, supporting approximately 7% annual rate-base growth, strengthening earnings potential and long-term shareholder returns.
The Zacks Rundown on PPLPPL’s Earnings EstimatesThe Zacks Consensus Estimate for 2026 and 2027 EPS indicates a year-over-year increase of 7.18% and 8.77%, respectively.
Image Source: Zacks Investment Research
Debt to CapitalPPL's debt-to-capital currently stands at 57.46%, lower than the Zacks Utility - Electric Power industry’s 62.33%.
Image Source: Zacks Investment Research
PPL’s Stock Price PerformanceIn the past month, the company’s shares have risen 1.6% against the industry’s 1.1% decline.
Image Source: Zacks Investment Research
PPL’s Zacks RankPPL currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Akcie společnosti Comfort Systems (FIX) od začátku roku vzrostly o 83,8 %, ale při forwardovém P/E 30,23 se obchodují výrazně nad oborovým průměrem 22,06.
Key Takeaways Comfort Systems surged 83.8% YTD, but its 30.23X forward P/E exceeds the industry's 22.06X.FIX's record $14.06B backlog and 50.3% revenue growth reflect strong data center demand.FIX faces project concentration risks, unchanged EPS estimates and potentially slowing growth.
Comfort Systems USA, Inc. (FIX - Free Report) has delivered an impressive stock market performance, supported by strong demand for data centers, expanding project backlogs and improving profitability. However, following its sharp rally, the company's elevated valuation raises questions about whether its growth prospects are already reflected in the share price.
Comfort Systems' shares have surged 83.8% year to date (YTD), significantly outperforming the Zacks Building Products - Air Conditioner and Heating industry's 17.6% gain. The stock has also outpaced the Zacks Construction sector, which declined 1.1%, and the S&P 500 Index, which advanced 13.9% during the same period.
FIX’s YTD Price Performance
Image Source: Zacks Investment Research
The rally reflects investors' confidence in Comfort Systems' expanding exposure to high-growth technology infrastructure markets. However, its premium valuation, substantial dependence on large industrial projects and unchanged earnings estimates suggest that investors should carefully assess the stock's risk-reward outlook.
FIX Stock's Premium Valuation Raises ConcernsComfort Systems is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 30.23X, representing a substantial premium to the industry's 22.06X. The stock also trades above its five-year median P/E of 23.45X, although it remains within its historical valuation range of 13.32X-48.14X.
FIX Stock’s Valuation (P/E F12M)
Image Source: Zacks Investment Research
This elevated valuation suggests that investors are already pricing in considerable earnings growth, supported by technology infrastructure spending and strong project execution. However, such expectations leave limited room for operational disappointments, project delays or slower-than-anticipated growth.
Comfort Systems currently has a Value Score of D, indicating that its valuation is less attractive despite strong fundamentals. Although its Growth Score of A, Momentum Score of A and overall VGM Score of A reflect favorable business prospects and share price momentum, the valuation premium increases downside risks if growth moderates.
Strong Quarterly Performance Supports FIX's Growth StoryComfort Systems' second-quarter 2026 results demonstrate the strength of its operating momentum. Quarterly revenues increased 50.3% year over year to $3.27 billion, supported by robust demand across its Mechanical and Electrical businesses. Electrical segment revenues increased 81%, while Mechanical segment revenues rose 40%. Same-store revenue growth reached 44%, reflecting broad-based organic expansion.
Profitability improved considerably, with gross margin expanding 240 basis points year over year to 25.9%. Operating margin increased to 17.1% from 13.8%, supported by improved project execution and operating leverage.
Earnings per share surged 91.9% to $12.53 from $6.53 a year earlier. Adjusted EBITDA increased approximately 80% to $600.5 million. Management expects full-year 2026 same-store revenue growth in the mid-to-high 30% range, indicating continued business strength.
Record Backlog and Data Center Demand Drive ProspectsComfort Systems' expanding backlog provides meaningful revenue visibility through 2027. As of June 30, 2026, backlog reached a record $14.06 billion, increasing 73% year over year and approximately 13% sequentially. Same-store backlog increased 69% year over year, reflecting sustained demand beyond acquisitions.
Technology infrastructure remains the company's primary growth driver. Technology-related projects accounted for approximately 58% of first-half 2026 revenues compared with 40% in the prior-year period.
Demand for data centers, artificial intelligence infrastructure and other mission-critical facilities is supporting new project opportunities. These projects require sophisticated mechanical systems, electrical installations, cooling capabilities and related infrastructure, areas where Comfort Systems maintains established expertise.
Management also indicated that project pipelines remained historically strong, providing confidence in continued construction activity.
Modular Expansion and Acquisitions Strengthen OpportunitiesComfort Systems is expanding its modular construction operations to address growing demand for prefabricated infrastructure solutions.
Modular operations represented approximately 17% of first-half 2026 revenues. The company expects dedicated modular production capacity to exceed 4 million square feet by 2026-end and reach approximately 5 million square feet by late summer 2027.
These investments should improve production capabilities and strengthen the company's position in technology infrastructure markets.
Strategic acquisitions provide another growth avenue. The May 2026 acquisition of Hunt Electric strengthens Comfort Systems' electrical capabilities and geographic presence. Management expects Hunt Electric to contribute approximately $250 million in annualized revenues.
Meanwhile, a strong balance sheet supports future expansion. As of June 30, Comfort Systems held approximately $1.85 billion in cash against $54.1 million in total debt, providing financial flexibility for investments and acquisitions.
Project Concentration and Execution Risks RemainDespite favorable demand trends, Comfort Systems faces risks associated with its increasing dependence on technology and industrial construction projects.
Industrial customers accounted for approximately 75% of first-half 2026 revenues. Such concentration creates exposure to changes in capital spending by large customers, particularly technology companies investing heavily in data centers.
Any slowdown in infrastructure investments, changes in project schedules or delays in customer spending could weaken bookings and backlog conversion.
Furthermore, rapid expansion creates execution challenges. Labor availability, rising wages, material costs and project complexity could pressure profitability. Fixed-price contracts also expose the company to potential cost overruns.
Comfort Systems expects capital expenditures to represent approximately 5% of 2026 revenues, reflecting substantial investment in production facilities and modular capacity.
Although second-quarter operating cash flow reached $1.14 billion, management acknowledged that advance customer payments contributed to its exceptional cash generation. Consequently, investors should not assume that this unusually strong quarterly cash performance will recur consistently.
FIX's Earnings Estimates Show Limited Revision MomentumDespite strong operational performance, analysts' earnings estimates have remained unchanged over the past 30 days, as shown below.
FIX’s EPS Estimate Revision Trend
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings is pegged at $47.65 per share, indicating 65% year-over-year growth. The consensus estimate for 2027 stands at $59.31 per share, suggesting an additional 24.5% increase.
Revenue estimates indicate growth of 42.1% in 2026 and 18.2% in 2027. Although these projections remain encouraging, unchanged earnings estimates suggest limited incremental upward revision momentum despite the stock's substantial appreciation.
Moreover, the expected moderation in revenue and earnings growth during 2027 could make sustaining the current valuation increasingly challenging.
How Does FIX Compare With Industry Peers?Comfort Systems competes with EMCOR Group (EME - Free Report) , Sterling Infrastructure (STRL - Free Report) and Quanta Services (PWR - Free Report) across mechanical, electrical and mission-critical infrastructure markets.
EMCOR benefits from growing demand for electrical construction, mechanical services and data center projects. EMCOR shares have gained 29.1% YTD and trade at 21.75X forward earnings. EMCOR's comparatively lower valuation could appeal to investors seeking exposure to similar infrastructure spending trends.
Sterling is expanding its presence in data centers, semiconductor facilities and advanced manufacturing projects. Sterling Infrastructure shares have surged 67.5% YTD, while its forward P/E stands at 20.91X. Sterling’s valuation offers a relatively lower earnings multiple despite strong infrastructure exposure.
Quanta benefits from electrical infrastructure modernization, power demand and large-scale construction opportunities. Quanta shares have surged 67.3% YTD. However, Quanta trades at 37.53X forward earnings, above Comfort Systems' multiple, reflecting elevated growth expectations across infrastructure markets.
FIX’s YTD Price Performance vs Peers
Image Source: Zacks Investment Research
Should Investors Exercise Caution on FIX Stock?Comfort Systems remains well-positioned to benefit from strong data center construction, expanding modular operations, strategic acquisitions and a record backlog. Its impressive operating performance and healthy balance sheet support favorable long-term business prospects.
However, the stock's 83.8% three-month rally, premium valuation and unchanged earnings estimates suggest that considerable optimism is already reflected in its share price. Increasing exposure to technology infrastructure projects, execution challenges and potentially moderating growth add to the risks.
While Comfort Systems' fundamental outlook remains encouraging, its current valuation offers limited protection against potential disappointments. The company's Zacks Rank #4 (Sell) reinforces a cautious near-term investment stance.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Given the sharp appreciation and elevated expectations, investors may be better positioned to avoid chasing the rally and wait for a more attractive entry point.
USD/JPY Talking Points:
USD/JPY continues to catch bids after pullbacks but bulls remain trepidatious at or around prior highs.
This has built an ascending triangle formation and this puts even more emphasis on the CPI report later this week. CPI has been a significant driver in the USD/JPY carry trade over the past five years, delivering some of the largest moves – in both directions.
With hindsight perhaps the comments from US Treasury Secretary Scott Bessent were ill-timed. The day he said that “I am the house, bet against me if you want” marked a higher-low in USD/JPY, and since then the pair has gained more than 500 pips. That was on September 9th, and in the month since the USD/JPY pair has shown respectable bullish price action, and if it weren’t for a series of comments from President Trump, Bessent and the Japanese Finance Minister, USD/JPY may well be back above the 160.00 handle, at this point.
I have long said that if the pair is going to reverse for anything more than a pullback, there’s going to need to be some help from data. And we can see this in the history of USD/JPY, where interventions or threats thereof might be able to stall a trend – but for buyers to actually sell out of positions there needs to be some legitimate fear of a change in the underlying backdrop.
And this really speaks to the nature of the situation, where comments saying that the USD/JPY spot rate do not reflect fundamentals. Because the fact is – they do, and it does, and so far markets have seen through threats and buyers haven’t been compelled to close out of longs.
But – if there’s one data item that has consistently been able to create that counter-trend movement, it’s been US CPI, as we can see from some of the larger reversals in the pair over the past four years.
USD/JPY Weekly Chart
Chart prepared by James Stanley; data derived from Tradingview
The Crux of the Problem
Inflation has printed at 1.9% for Japan over the past two months. The Bank of Japan hiked rates anyways in September despite inflation being below their target. This is quite abnormal for a bank that tested some very experimental monetary policy while consistently leaning more and more dovish.
And one look at the demographic scenario in Japan and it makes sense as to why. With an aging and dwindling population, growth is already an uphill battle, and after decades of disinflation and deflation – much of which was pushed along by a strong Yen – the political volatility in the country pushed economics as a priority. It’s just, an uphill battle when you’re dealing with a population expected to decrease by a third over the next 30ish years.
But, when the comment is made that the spot price doesn’t reflect fundamentals, that’s what speaks against it – inflation in the US remains higher, rate expectations are more hawkish in response to that inflation, and frankly, there’s still a carry trade in play with the rate disparity between the two nations.
And if a fund or a bank is borrowing capital in Japan at lower rates, and then investing elsewhere, the primary risk is currency risk as a continually weakening Yen could eviscerate any profits seen from the spread. So, hedging that risk makes sense and this is where a long USD/JPY trade can come into play.
When that hedge looks more likely to lose capital – such as a large change in underlying inflation rates, such as we saw from the US in November of 2022 or 2023, or July of 2024; or perhaps a jump in inflation such as what we saw in April of 2024 – market participants are going to factor that in.
It’s the very essence of responding to and incorporating fundamentals. But with seemingly everyone pushing in one singular direction, these trades can become incredibly crowded, and that perhaps acts as a magnifier of sorts, so that when some form of change does show, the result can seem more outsized than normal.
USD/JPY Weekly Chart
Chart prepared by James Stanley; data derived from Tradingview
Interventions
Interventions in the open market are not ideal, nor should they be. It essentially involves the central bank jumping in to manipulate a free market, using their own cash reserves, to influence a trade in the opposite direction that their own monetary policy is encouraging. Part of the design is to shake out the crowded trades as looked at above, but, in reality, the half life of these moves is often limited in scope. Because, after all, the fundamental backdrop that produced the situation in the first place very much remains in place.
What makes the most recent episode as unique is who is involved, as this time, it was a dual intervention with both the US and Japan taking part. Also unique is the fact that the US Treasury Secretary behind the push has extensive experience in currency markets. Yes, that same Scott Bessent who is currently being called out by markets and social media for his “I am the house” quote. He was a key member of Quantum and the George Soros team that broke the Bank of England in 1992. Bessent’s role at Quantum was executing FX trades and in this most recent example of intervention, it was a unique approach of the US Treasury asking the NY Federal Reserve to do a rate check. These normally happened from the Japanese side, which basically involves a very obvious move from the central bank in orchestrating dialog with banks designed to scare them into action. One of these episodes allegedly took place earlier in the year, in January, but the episode in July was far more forceful as Bessent took the next step of getting the US Treasury to actually go out and buy Japanese Yen in the marketplace.
Why would Bessent be so interested in the matter, aside from his obvious history with Foreign Exchange markets? Well in his current role he’s tasked with managing US Treasury debt and there’s a plethora of long-term US debt coming due in the next year. This is part of the reason why yields have scaled so much higher, the thought of that additional supply has driven longs to sell, and many funds are shorting Treasuries in anticipation. Well Japan is the largest national holder of US debt, and if they are to go into markets to intervene by buying JPY against the Dollar, they would probably be selling Treasuries to fund the trade. This means more supply, and higher yields, at a time when Bessent can ill afford such a thing.
This backdrop helps to explain why USD/JPY continues to see so much bullish price action after these pullbacks. Because, frankly, with still positive carry on the long side of the pair, evidence of support sets up an attractive technical backdrop to go with a bullish fundamental bias in the pair.
The problem is the theoretically capped upside given those intervention comments over the past couple of months.
USD/JPY Daily Chart
Chart prepared by James Stanley; data derived from Tradingview
USD/JPY Ascending Triangle to the Line in the Sand
The month of August was actuall quite similar to what’s played out since early-September. There’s a series of higher-lows as bulls have gotten more and more aggressive, but there’s also a line-in-the-sand where that bullish price action has suddenly ceased. In August, that line was at 160. More recently, it’s 159.
But notably neither price has seen an actual intervention, as it was merely threats of intervention that pushed prices lower. And this is what sets the stage for CPI on Wednesday as a big print, which would probably push rate hike expectations higher, could compel a breakout in the pair.
The actual hard line in the sand that was defended by action before was 164. But that 160 spot, much like we saw in August as bulls started to tip-toe above, may be vulnerable, as might 159.
On the flip side, a big miss in CPI would hit rate hike expectations and, like we saw back in November of 2022 or 2023, or again in July of 2024, there might be a stampede for the exits as longs look to get out ahead of what would feel like an inevitable pullback.
This puts a lot of emphasis on the CPI print on Wednesday because, after all, fundamentals impact the matter. It’s just perhaps not always in the way that we expect, or the way that some want.
USD/JPY Four-Hour Chart
Chart prepared by James Stanley; data derived from Tradingview
--- written by James Stanley, Senior Market Analyst, Global Macro
Společnost Progressive by měla ve 3. čtvrtletí 2026 vykázat zisk na akcii ve výši 4,43 USD, což představuje meziroční nárůst o 9,4 %, při tržbách 23,4 mld. USD.
Key Takeaways Progressive's Q3 earnings are projected to rise 9.4% to $4.43 per share, with revenues up 5.4% to $23.4B.Premium growth, higher investment income & expanding personal auto policies are likely to aid Q3 results.Higher underwriting costs may dampen PGR, though an 89.4 combined ratio signals continued profitability. The Progressive Corporation (PGR - Free Report) is expected to witness an improvement in its bottom line but a decline in its top line when it reports third-quarter 2026 results on Oct. 14, before the opening bell.
The Zacks Consensus Estimate for PGR’s third-quarter revenues is pegged at $23.4 billion, indicating 5.4% growth from the year-ago reported figure.
The consensus estimate for earnings is pegged at $4.43 per share. The Zacks Consensus Estimate for PGR’s third-quarter earnings has moved 2.5% north in the past seven days. The estimate indicates a year-over-year increase of 9.4%.
Decent Earnings Surprise HistoryProgressive’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed in one.
What the Zacks Model Unveils for PGROur proven model does not conclusively predict an earnings beat for Progressive this time around. This is because a stock needs to have the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) that increases the chances of an earnings beat. That is not the case, as you can see here.
You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Earnings ESP: PGR has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $4.43.
Zacks Rank: PGR carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Factors Likely to Shape Q3 ResultsGrowth in premiums, higher net investment income and increased fee and service revenues are likely to have aided Progressive’s third-quarter performance. Improving trends across its personal auto and commercial lines businesses are likely to have further supported the company’s results.
A diversified product portfolio, strong competitive position and solid contributions from its Vehicle and Property segments are expected to have supported premium growth. Healthy policy retention and an expanding base of policies in force are likely to have driven higher net premiums earned. The Zacks Consensus Estimate for net premiums earned is pegged at $21.9 billion, suggesting a 5.1% increase from the year-ago quarter.
The Personal Auto segment is expected to have gained from increased new business applications and policy renewals, supported by higher advertising expenditures, competitive pricing strategies and agency incentive initiatives. Continued expansion across both agency and direct distribution channels is likely to have contributed to growth in policies in force. The consensus estimate for personal auto policies in force stands at 39.4 million.
Net investment income is likely to have benefited from growth in the company’s invested asset base. The Zacks Consensus Estimate is pegged at approximately $1 billion, indicating an 11% improvement from the prior-year quarter. Progressive is also expected to have generated pretax net realized gains on securities, with the consensus estimate standing at $61 million.
However, elevated loss and loss-adjustment expenses, higher policy acquisition costs and increased other underwriting expenses are likely to have weighed on the company’s overall cost structure. The consensus estimate for the expense ratio stands at 20.47.
Disciplined underwriting practices and relatively modest catastrophe-related losses are expected to have supported underwriting margins. The Zacks Consensus Estimate for the combined ratio is pegged at 89.4, reflecting continued underwriting profitability and operational efficiency.
Stocks to ConsiderSome P&C insurance stocks with the right combination of elements to deliver an earnings beat this time around are:
Arch Capital Group (ACGL - Free Report) has an Earnings ESP of +9.62% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for third-quarter 2026 earnings is pegged at $1.96 per share, indicating a 29.2% year-over-year decrease.
ACGL’s earnings beat estimates in the last four reported quarters.
The Travelers Companies (TRV - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for third-quarter 2026 earnings is pegged at $6.90 per share, indicating a year-over-year decrease of 15.2%.
TRV’s earnings beat estimates in each of the last four reported quarters.
Cincinnati Financial Corporation (CINF - Free Report) has an Earnings ESP of +9.52% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for third-quarter 2026 earnings is pegged at $1.91 per share, indicating a year-over-year decrease of 33%.
CINF’s earnings beat estimates in three of the last four reported quarters, while missing in one.
Jabil rozšiřuje své automobilové portfolio o technologie pro elektromobily, ADAS, konektivitu a nabíjení, aby těžil z rozvoje trhu s vozidly nové generace.
Key Takeaways JBL expands its automotive business with EVs, advanced safety and connected mobility.Its portfolio spans ADAS, infotainment, high-performance computing, battery management and charging equipment.Jabil's global supply chain boosts efficiency and speeds up technology launches. Jabil Inc. (JBL - Free Report) is expanding its footprint in the automotive industry as automakers increasingly adopt electric vehicles, advanced safety systems and connected mobility solutions. The company helps automotive manufacturers and technology suppliers develop innovative products to meet evolving vehicle requirements.
Jabil’s automotive portfolio includes advanced driver-assistance systems (ADAS), vehicle connectivity, infotainment and high-performance computing platforms. It also provides electrification solutions, including battery management systems, inverters, converters and charging equipment, along with LiDAR, radar and camera technologies that support safer, more connected vehicles.
The company offers services across the product development lifecycle, from design and prototyping to testing, industrialization and large-scale manufacturing. Its global production network and supply-chain expertise help customers maintain product quality, improve operational efficiency and accelerate the launch of new automotive technologies.
In addition, Jabil supports the transition toward software-defined commercial vehicles which use connected electronic systems to enable over-the-air updates and improve vehicle functionality. These capabilities position the company to benefit from the growing adoption of next-generation automotive technologies.
How Are Competitors Performing in the Automotive Industry?Jabil faces fierce competition from Sanmina Corporation (SANM - Free Report) and Flex Ltd. (FLEX - Free Report) . Sanmina manufactures automotive electronics, including ADAS, battery control modules, power conversion systems and infotainment components. It continues to secure new automotive programs from existing and new customers, with some projects moving from initial development into full-scale production. Sanmina uses automated manufacturing and automotive-quality processes to improve product reliability and production efficiency.
Flex is advancing software-defined vehicle technology through automotive electronic systems that support centralized computing and connectivity. The company is helping automakers improve supply-chain transparency through secure data-sharing solutions. Flex provides power electronics and charging systems for electric and hybrid vehicles, supporting the shift toward vehicle electrification.
JBL’s Price Performance, Valuation and EstimatesJabil has gained 53.2% in the past year compared with the industry’s growth of 51.9%.
Image Source: Zacks Investment Research
Going by the price/earnings ratio, the company’s shares currently trade at 16.9 forward earnings, lower than 20.35 for the industry.
Image Source: Zacks Investment Research
Earnings estimates for Jabil for 2027 have moved up 6.2% to $17.61 per share over the past 60 days, while the same for 2028 has increased 7.4% to $22.02.
Image Source: Zacks Investment Research
Jabil currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Quanta Services očekává v roce 2026 růst tržeb divize Technology & Load Centers o 220–240 % díky poptávce po datových centrech a infrastruktuře pro umělou inteligenci.
Key Takeaways Quanta expects 220%-240% load center revenue growth in 2026, fueled by AI and data center demand.Acquisitions and large projects boost Quanta's capabilities as its backlog hits a record $53.4B.Labor shortages, project delays and tougher comparisons may challenge Quanta's growth momentum. Quanta Services, Inc. (PWR - Free Report) expects significant growth in its Technology & Load Centers business in 2026, supported by accelerating data center construction, artificial intelligence (AI) infrastructure investments and rising power requirements. Management projects revenue growth of 220%-240% in this market, highlighting expanding opportunities in large-scale infrastructure development.
Data Center Demand Drives Quanta's GrowthTechnology & Load Centers accounted for approximately 10% of Quanta's 2025 revenues. The projected growth reflects increasing demand for electrical and mechanical infrastructure supporting large-load facilities, along with contributions from acquisitions.
A full year of contributions from Dynamic Systems and Tri-City Group, alongside partial-year contributions from Phalcon, should strengthen Quanta's execution capabilities. Large, multi-year construction programs are also expanding its addressable market.
Quanta's integrated electrical, mechanical and fabrication capabilities position it to capture a greater share of complex projects. Its self-performing workforce provides additional advantages in meeting demanding construction schedules.
Can Quanta Sustain This Momentum?Quanta's second-quarter 2026 revenues increased 41.1% year over year to $9.56 billion, while total backlog reached a record $53.4 billion. Management raised its full-year revenue guidance to $39.3-$39.7 billion, reinforcing confidence in sustained infrastructure demand.
However, maintaining triple-digit growth could become challenging as acquisition-related benefits normalize and comparisons strengthen. Permitting delays, skilled-labor shortages, supply-chain constraints and potential changes in data center investment plans could also affect project execution.
Nevertheless, rising electricity consumption, grid modernization and expanding AI infrastructure requirements support Quanta's multi-year growth prospects, even if the exceptional pace of load center expansion moderates.
How Do EMCOR and Comfort Systems Compete With Quanta?EMCOR Group (EME - Free Report) and Comfort Systems USA (FIX - Free Report) are expanding their exposure to data center construction and AI infrastructure, competing with Quanta in the growing technology and load center market.
EMCOR benefits from strong demand for electrical and mechanical construction services supporting hyperscale data centers and mission-critical facilities. EMCOR's expanding project backlog, skilled workforce and recent electrical acquisitions strengthen its ability to secure large infrastructure contracts. Moreover, EMCOR's integrated service capabilities support growth as customers increase investments in power-intensive facilities.
Comfort Systems is also benefiting from rising demand for advanced mechanical, electrical and plumbing solutions across data centers and technology infrastructure projects. Comfort Systems' growing technology-related backlog and strategic acquisitions are improving its project execution capabilities and geographic reach. Its emphasis on modular construction and prefabrication provides additional competitive advantages.
However, both EMCOR and Comfort Systems face skilled-labor constraints, project delays and rising execution costs, which could affect profitability despite favorable demand trends.
PWR Stock’s Price Performance & Valuation TrendPWR stock has gained 64% over the past year, outperforming the Zacks Engineering - R and D Services industry, the Zacks Construction sector and the S&P 500 Index.
PWR Price Performance
Image Source: Zacks Investment Research
PWR stock is currently trading at a premium compared with the industry peers, with a forward 12-month price-to-earnings (P/E) ratio of 37.53, as evidenced by the chart below.
PWR Valuation
Image Source: Zacks Investment Research
Earnings Estimate Revision of PWRPWR’s earnings estimates for 2026 and 2027 are pinned at $16.70 and $19.41 per share, respectively, reflecting an upward trend over the past 30 days. The revised estimates for 2026 and 2027 imply year-over-year growth of 55.4% and 16.2%, respectively.
Image Source: Zacks Investment Research
Quanta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dceřiná společnost VideoRay firmy AeroVironment podpoří tým AEVEX, který byl vybrán pro prototyp modernizace námořních odminovacích schopností amerického námořnictva.
Key Takeaways AeroVironment's VideoRay joins an AEVEX-led team selected for a Navy mine-countermeasure prototype.VideoRay demonstrated autonomous underwater operations launched from an uncrewed surface vessel.VideoRay builds on a $92.6 million Navy contract awarded in 2024 for production and development.
AeroVironment (AVAV - Free Report) is expanding its presence in naval defense applications, with its wholly owned subsidiary VideoRay selected to support a team participating in a U.S. Navy mine-countermeasure modernization effort.
On Oct. 8, 2026, AeroVironment announced that VideoRay was supporting an AEVEX-led team selected for a prototype Other Transaction Agreement following the U.S. Navy and Department of War Innovation Unit’s Mine Countermeasure Modernization Prize Challenge. BlackSea Technologies, now part of AEVEX Maritime Systems, was one of three companies to receive challenge prizes after successfully completing demonstrations.
During competitive in-water testing, VideoRay demonstrated an autonomous mine-countermeasure remotely operated vehicle launched from an AEVEX uncrewed surface vessel. The integrated system used autonomous launch-and-recovery capabilities, allowing operators to conduct missions beyond the horizon from a remote ground control station. The demonstration included vessel transit, station keeping, underwater target investigation, simulated mine neutralization and post-engagement assessment.
VideoRay’s Mission Specialist Defender is a modular underwater robotic platform designed to accommodate different sensors, manipulators and specialized payloads. Its open architecture allows the system to integrate with different surface vessels and mission equipment, potentially supporting a range of underwater intervention and mine-countermeasure requirements.
The development also builds on VideoRay’s existing relationship with the U.S. Navy. In 2024, the company received a five-year contract valued at $92.6 million for continued production, sustainment and development of the Defender platform. The Navy had previously selected the system as the base platform for its MK20 Defender remotely operated vehicle supporting the Maritime Expeditionary Standoff Response program.
Further adoption of these technologies could support demand for underwater robotic platforms, integration services and long-term sustainment.
Defense Companies Gain From Autonomous Maritime ModernizationNaval forces are increasingly exploring uncrewed systems to further improve operational flexibility, reduce personnel exposure and strengthen capabilities in complex maritime environments. Other companies with exposure to the broader defense modernization market include:
Huntington Ingalls Industries (HII - Free Report) is a major U.S. military shipbuilder that provides naval platforms and related services. Its position in the naval defense sector makes it relevant to broader investment in maritime capabilities.
Northrop Grumman (NOC - Free Report) develops advanced defense technologies, including autonomous systems, sensors and mission solutions. Its portfolio reflects the wider industry focus on integrating advanced technologies into military operations.
AVAV Stock’s Earnings EstimatesThe Zacks Consensus Estimate for fiscal 2027 earnings per share implies a decrease of 1.81% year over year.
Image Source: Zacks Investment Research
AVAV Stock Trades at a DiscountIn terms of valuation, AVAV’s forward 12-month price-to-sales (P/S) is 2.96X, a discount to the industry’s average of 6.92X.
Image Source: Zacks Investment Research
AVAV Stock’s Price PerformanceIn the past three months, the company’s shares have lost 3.3% compared with the industry’s 14.6% decline.
Image Source: Zacks Investment Research
AVAV’s Zacks RankThe company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Společnost Dutch Bros zvažuje koupi až 65 poboček Salad and Go ve čtyřech státech, které by přestavěla na vlastní provozovny, ale svou původní nabídku nezvýší.
Key Takeaways Dutch Bros is exploring the acquisition of up to 65 Salad and Go sites in four states for shop conversions.BROS opened 48 shops in Q2 2026 and targets at least 185 openings this year on its path to 2,029 by 2029.Dutch Bros won't increase its original offer, but has secured about 90% of its 2029 development pipeline.
Dutch Bros Inc. (BROS - Free Report) is exploring opportunities to accelerate its nationwide expansion through a proposed acquisition of up to 65 Salad and Go locations across Arizona, Nevada, Oklahoma and Texas. The transaction could strengthen the company's presence in established markets while providing additional growth opportunities through the conversion of existing drive-thru sites.
The proposed acquisition involves existing drive-thru properties that Dutch Bros initially planned to convert into company-operated shops beginning in 2027. Management believes the existing Salad and Go locations are comparable in size to Dutch Bros shops, potentially simplifying conversions and accelerating development. Under the original proposal, conversions were expected to begin in 2027.
Importantly, Dutch Bros' development momentum provides a solid foundation for further expansion. The company opened 48 shops in the second quarter of 2026, bringing its total footprint to 1,225 locations. It expects at least 185 openings in 2026 and has secured approximately 90% of the development pipeline required to achieve its goal of 2,029 shops by 2029. Its expansion strategy is further supported by a pipeline of more than 525 operator candidates and improving new-shop productivity.
However, the Salad and Go transaction remains uncertain. On Aug. 31, Dutch Bros announced that it would not increase its original offer for the properties, although it remained engaged in the process. This decision underscores management's disciplined approach to capital allocation and its focus on investments offering attractive returns.
While securing the sites could provide an additional growth catalyst, Dutch Bros' established development pipeline, improving shop productivity and continued expansion into new markets should support its long-term growth trajectory even without the transaction.
Strategic Site Selection Fuels Expansion OpportunitiesDutch Bros' proposed acquisition of up to 65 Salad and Go sites highlights its focus on securing attractive drive-thru locations and increasing market density. Peers Starbucks Corporation (SBUX - Free Report) and Shake Shack Inc. (SHAK - Free Report) are similarly emphasizing disciplined development and strong unit economics to support expansion.
Starbucks is refining its development strategy under the Back to Starbucks initiative, prioritizing profitable locations and enhanced customer experiences. It expects 600-650 net new coffeehouses in fiscal 2026, largely supported by international expansion. North American company-operated growth may remain modest through fiscal 2027 as the company strengthens site selection and accelerates coffeehouse upgrades, targeting at least 1,500 by fiscal 2026-end.
Shake Shack plans to open 60-65 company-operated Shacks and 40-45 licensed locations in 2026. Newer restaurants are generating cash-on-cash returns exceeding 30%, supporting further expansion. Management is also exploring smaller restaurant formats with lower construction costs and selective drive-thru opportunities to access additional markets.
Both competitors highlight the importance of location quality, capital discipline and attractive returns, reinforcing Dutch Bros' approach to evaluating conversion opportunities and sustaining long-term growth.
BROS’ Price Performance, Valuation & EstimatesShares of Dutch Bros have declined 28% in the past six months, underperforming the Zacks Retail - Restaurants industry, the broader Retail and Wholesale sector and the S&P 500 Index.
BROS Stock’s Six-Month Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, Dutch Bros stock trades at a forward price-to-sales ratio of 2.61, below the industry’s average of 2.86.
BROS’ P/s Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BROS’ 2026 earnings per share (EPS) implies a year-over-year uptick of 29%. The EPS estimates for 2026 have increased in the past 30 days.
EPS Trend of BROS Stock
Image Source: Zacks Investment Research
Dutch Bros currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Akcie F5 (FFIV) v pondělí dosáhly nového 52týdenního maxima na úrovni 484,49 USD poté, co RBC zvýšila cílovou cenu z 508 USD na 525 USD a ponechala doporučení „outperform“.
F5, Inc. (NASDAQ:FFIV – Get Free Report)’s share price reached a new 52-week high on Monday after Royal Bank Of Canada raised their price target on the stock from $508.00 to $525.00. Royal Bank Of Canada currently has an outperform rating on the stock. F5 traded as high as $484.49 and last traded at $480.9850, with a volume of 992 shares trading hands. The stock had previously closed at $479.83.
Several other brokerages also recently issued reports on FFIV. Barclays raised their price objective on shares of F5 from $386.00 to $397.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 28th. Weiss Ratings upgraded shares of F5 from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Wall Street Zen upgraded F5 from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of F5 in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. boosted their target price on shares of F5 from $500.00 to $515.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, F5 has an average rating of “Hold” and a consensus target price of $426.00.
Check Out Our Latest Report on F5
Insider Activity In related news, insider John Maddison sold 204 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $406.24, for a total transaction of $82,872.96. Following the completion of the sale, the insider owned 1,149 shares of the company’s stock, valued at $466,769.76. This represents a 15.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas Fountain sold 1,208 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $414.63, for a total value of $500,873.04. Following the completion of the sale, the executive vice president owned 8,060 shares in the company, valued at $3,341,917.80. The trade was a 13.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 16,829 shares of company stock worth $6,815,302 over the last quarter. Corporate insiders own 0.48% of the company’s stock. Hedge Funds Weigh In On F5 A number of hedge funds have recently modified their holdings of FFIV. SJS Investment Consulting Inc. lifted its holdings in F5 by 963.6% in the 1st quarter. SJS Investment Consulting Inc. now owns 117 shares of the network technology company’s stock worth $34,000 after purchasing an additional 106 shares during the last quarter. Capital Advisors Ltd. LLC grew its stake in shares of F5 by 113.8% in the 1st quarter. Capital Advisors Ltd. LLC now owns 124 shares of the network technology company’s stock valued at $36,000 after purchasing an additional 66 shares during the period. Persistent Asset Partners Ltd bought a new stake in shares of F5 in the 2nd quarter worth about $36,000. Bell Investment Advisors Inc acquired a new stake in F5 during the 2nd quarter valued at $49,000. Finally, Elevation Wealth Partners LLC grew its holdings in F5 by 373.1% during the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the network technology company’s stock worth $51,000 after acquiring an additional 97 shares during the last quarter. 90.66% of the stock is currently owned by institutional investors and hedge funds.
F5 Stock Down 0.6% The stock’s 50-day moving average price is $418.31 and its 200-day moving average price is $384.11. The company has a market capitalization of $27.01 billion, a price-to-earnings ratio of 37.94, a price-to-earnings-growth ratio of 4.55 and a beta of 1.03.
F5 (NASDAQ:FFIV – Get Free Report) last issued its quarterly earnings results on Monday, July 27th. The network technology company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of $4.00 by $0.73. F5 had a net margin of 21.95% and a return on equity of 21.54%. The business had revenue of $865.08 million during the quarter, compared to analyst estimates of $834.60 million. During the same quarter last year, the business posted $4.16 earnings per share. F5’s revenue for the quarter was up 10.9% compared to the same quarter last year. F5 has set its Q4 2026 guidance at 4.140-4.260 EPS and its FY 2026 guidance at 17.210-17.330 EPS. On average, equities research analysts anticipate that F5, Inc. will post 13.65 EPS for the current year.
F5 Company Profile (Get Free Report)
F5, Inc develops application delivery, security and management technologies that help organizations deploy, protect and optimize applications across data centers, public clouds, edge environments and distributed networks. Its offerings are designed to support application availability, performance, scalability and security across hybrid and multi-cloud architectures.
The company’s portfolio includes BIG-IP application delivery and security solutions, NGINX web and application delivery technologies, and F5 Distributed Cloud services.
Read More Five stocks we like better than F5 5 Retail Picks to Watch as the Holiday Shopping Season Nears C.H. Robinson Bets Its AI Story on RXO—But the Market Isn’t Sold Google’s $13 Billion Nordic Bet Points to a New Global Front in the AI Power Race 3 Stocks Raise Dividends, But Which Has Room to Keep Growing? Receive News & Ratings for F5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F5 and related companies with MarketBeat.com's FREE daily email newsletter.
AMN Healthcare zvýšila ve 2. čtvrtletí 2026 tržby divize Nurse and Allied Solutions o 11 % na 422 milionů USD, ale ve 3. čtvrtletí očekává pokles upravené marže EBITDA na 6,5–7 %.
Key Takeaways AMN Healthcare benefits from rising staffing demand, technology investments and higher-margin services.Nurse and Allied revenues rose 11% in Q2 2026, while Passport users grew 33% to more than 400,000.Pricing pressure, weak physician and technology revenues and margin normalization may risk AMN's growth.
AMN Healthcare Services, Inc. (AMN - Free Report) is well positioned for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by rising healthcare staffing demand, expanding technology-enabled workforce solutions and growth opportunities in higher-margin technology and language services. However, persistent pricing competition, weakness in its physician and technology businesses, and earnings normalization and execution risks may weigh on its performance.
Shares of this Zacks Rank #3 (Hold) company have surged 131.7% year to date, outperforming the industry's 16% decline and the S&P 500’s 14.7% rise.
This renowned player in the healthcare total talent services space has a market capitalization of $1.41 billion. The company projects 144.1% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 96.63%.
Image Source: Zacks Investment Research
Factors Favoring AMN StockRising Healthcare Staffing Demand: AMN Healthcare is positioned to benefit from persistent healthcare workforce shortages, supported by an aging population, rising chronic disease prevalence and physician supply constraints. The projected shortage of up to 86,000 physicians by 2036 highlights the need for flexible staffing solutions. AMN's second-quarter 2026 Nurse and Allied Solutions revenues grew 11% year over year to $422 million. Travel nurse and allied volumes increased 6% and 7%, respectively, marking their highest growth rates in four years. Management expects both categories to deliver volume growth exceeding 10% in the third quarter, supporting continued momentum.
Expanding Technology-Enabled Workforce Solutions: AMN's investments in automation, artificial intelligence and workforce analytics strengthen its competitive positioning. Its Passport application surpassed 400,000 users in the second quarter of 2026, increasing 33% year over year, while monthly active users rose more than 50%. The acquisition of Jaide Health expands AI-enabled language interpretation services, while WorkWise enhancements improve workforce optimization capabilities. Furthermore, AMN's research covering more than 2,000 hospitals found that 11 of 12 digital investment measures were associated with better patient experiences. These developments reinforce the company's ability to address evolving healthcare workforce needs through integrated technology and staffing services.
Expanding Higher-Margin Technology and Language Services: AMN can strengthen its competitive positioning by expanding specialized services beyond traditional staffing, particularly language interpretation and workforce management solutions. These offerings help hospitals address communication barriers, streamline staffing processes and improve operational efficiency. As healthcare providers increasingly prioritize coordinated workforce management and patient experience, AMN's integrated service portfolio could support deeper client relationships, diversify revenue sources and improve its business mix. Recent acquisitions of Jaide Health and ESSENTIAL Leadership Assessment further expand its AI-enabled language access and leadership advisory capabilities, creating opportunities to deepen client relationships and capture demand for specialized workforce solutions.
Downsides of AMN StockPersistent Pricing Competition: Intense competition across healthcare staffing and workforce technology markets continues to constrain pricing opportunities. Despite rising travel nurse demand, AMN has not experienced sustained bill-rate increases. Management noted that a larger supplier base is limiting pricing recovery. Language services pricing declined 8% year over year in the second quarter of 2026, contributing to an 8% revenue decline despite stable volumes. Management expects pricing compression to continue through the remainder of 2026, limiting revenue growth and profitability.
Weakness in Physician and Technology Businesses: Uneven performance across AMN's operating segments remains a concern. Physician and Leadership Solutions revenues declined 6% year over year to $165 million in the second quarter of 2026, reflecting an 8% contraction in locum tenens revenues. Technology and Workforce Solutions revenues fell 15% to $87 million, while vendor management system revenues declined 20%. Management projects third-quarter revenue declines of 5%-7% and 11%-13% for these segments, respectively. Continued weakness could offset growth in Nurse and Allied Solutions and constrain consolidated performance.
Earnings Normalization and Execution Risks: AMN's second-quarter 2026 profitability benefited from approximately $27 million in favorable revenue adjustments, which added 370 basis points to adjusted EBITDA margin. These benefits are not expected to recur in the third quarter. Management projects an adjusted EBITDA margin of 6.5%-7%, compared with 10.9% in the second quarter. International nurse growth also faces visa interview delays, potentially limiting expansion in 2027. The competitive renewal process for its Kaiser contract, which expires at the end of 2026, creates additional uncertainty surrounding future revenues and contract terms.
Estimate TrendAMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 7.1% to $3.32.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $648 million and 22 cents, respectively, suggesting 2.1% growth and a 43.6% decline from the year-ago reported numbers.
Key PicksSome better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Papa John's snížila výhled srovnatelných tržeb v Severní Americe pro rok 2026 na pokles o 6 až 8 % a pozastavila výplatu dividendy; její akcie ten den klesly o 17,18 %.
NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Papa John's International, Inc. (NASDAQ: PZZA) that two senior officers, President and Chief Executive Officer Todd Allan Penegor and former Chief Financial Officer Ravi Thanawala, are named as individual defendants facing control person claims under Section 20(a) in a pending securities class action covering purchases between August 7, 2025 and August 5, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
PZZA INVESTOR ALERT
The action centers on the August 6, 2026 announcement in which Papa John's cut its 2026 North American comparable sales outlook from a 3% decline at the midpoint to an annual decline of 6-8% and suspended its dividend. PZZA fell $5.11 per share, or about 17.18%, to close at $24.64. The window to apply for lead plaintiff closes on November 2, 2026.
The Named Individual Defendants
Penegor served as President, Chief Executive Officer, and a Director for the entire Class Period. Thanawala served as Chief Financial Officer and EVP International until November 18, 2025, then as Chief Financial Officer and President of the North American business until June 30, 2026, remaining in an advisory capacity through July 31, 2026. Both are alleged to have possessed the power and authority to control the content of the Company's SEC reports, press releases, and presentations to securities analysts and institutional investors.
Alleged Control Person Liability
Authority over the content and timing of quarterly earnings releases and the North American comparable sales guidance issued during the Class Period.Access to internal reporting on transaction trends, promotional spending, and innovation pipeline performance before those figures reached the investing public.Signature and certification authority over periodic SEC filings under Sections 302 and 906 of the Sarbanes-Oxley Act.The ability, as alleged, to prevent or correct statements characterizing the transformation as delivering sustainable, profitable growth.Oversight of roughly $22 million in supplemental marketing and franchisee subsidies tied to the 2026 promotional and innovation calendar.Under Section 20(a) of the Exchange Act, officers alleged to have controlled a company that violated Section 10(b) may be held jointly liable for resulting investor losses. Sarbanes-Oxley Certification Obligations
Sarbanes-Oxley certifications require signing officers to attest that periodic reports contain no untrue statement of material fact. The complaint contends those certifications were inaccurate because the transformation was allegedly taking longer than expected and ultimately required a sharp pivot toward promotional discounting that was not disclosed to shareholders.
"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. The complaint contends that shareholders were told the transformation was working while conditions allegedly pointed toward continued market share losses. Section 20(a) exists so that the individuals who controlled those disclosures can be held accountable." -- Joseph E. Levi, Esq.
Submit your information to learn more or call (212) 363-7500.
Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the PZZA Lawsuit
Q: Who are the defendants named in the PZZA lawsuit? A: The complaint names Papa John's International, Inc. and individual defendants who were senior investors during the class period, including Todd Allan Penegor and Ravi Thanawala.
Q: What court was the PZZA class action filed in? A: The case was filed in the United States District Court for the Western District of Kentucky, Louisville Jury Division, governed by the Private Securities Litigation Reform Act of 1995.
Q: What is the PZZA class action lawsuit about? A: A securities class action has been filed against Papa John's International, Inc. (NASDAQ: PZZA) alleging materially false and misleading statements between August 7, 2025 and August 5, 2026. Shares fell approximately 17.18% after the Company disclosed an 8.3% decrease in North American comparable sales, the suspension of its dividend, and a reduction of its 2026 North American outlook to a 6-8% annual decline. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What do PZZA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.
Q: What if I already sold my PZZA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Whirlpool Corporation (NYSE:WHR – Get Free Report)’s share price reached a new 52-week low on Monday. The company traded as low as $28.23 and last traded at $28.5110, with a volume of 88,846 shares traded. The stock had previously closed at $28.83.
Analyst Upgrades and Downgrades A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Whirlpool from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. BNP Paribas Exane assumed coverage on Whirlpool in a research report on Monday, July 13th. They issued a “neutral” rating and a $43.00 price target on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Whirlpool in a research report on Wednesday, August 5th. The Goldman Sachs Group set a $41.00 target price on Whirlpool in a research note on Monday. Finally, Raymond James Financial restated a “market perform” rating on shares of Whirlpool in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Whirlpool has a consensus rating of “Reduce” and a consensus price target of $38.56.
View Our Latest Research Report on WHR
Whirlpool Stock Performance The firm’s 50 day moving average price is $36.79 and its 200-day moving average price is $42.02. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 9.87, a P/E/G ratio of 12.81 and a beta of 1.21. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.15 and a quick ratio of 0.71. Whirlpool (NYSE:WHR – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.15). Whirlpool had a net margin of 1.17% and a return on equity of 4.18%. The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the previous year, the company earned $1.34 earnings per share. Whirlpool’s revenue for the quarter was down 6.8% compared to the same quarter last year. Whirlpool has set its FY 2026 guidance at 2.500-3.000 EPS. On average, analysts anticipate that Whirlpool Corporation will post 2.25 earnings per share for the current year.
Institutional Inflows and Outflows Several institutional investors and hedge funds have recently made changes to their positions in the stock. Primecap Management Co. CA bought a new position in shares of Whirlpool during the 2nd quarter worth about $141,801,000. RWWM Inc. boosted its position in shares of Whirlpool by 191.6% during the 1st quarter. RWWM Inc. now owns 2,422,618 shares of the company’s stock valued at $130,628,000 after acquiring an additional 1,591,849 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Whirlpool during the 2nd quarter valued at about $61,003,000. Nykredit A S bought a new stake in Whirlpool in the second quarter valued at about $51,953,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Whirlpool in the second quarter valued at about $24,601,000. Institutional investors own 90.78% of the company’s stock.
Whirlpool Company Profile (Get Free Report)
Whirlpool Corporation is a global manufacturer and marketer of home appliances, serving consumers through a portfolio of well-known brands that includes Whirlpool, Maytag, KitchenAid, Amana and JennAir. Its products are sold through retailers, distributors and other channels to residential customers in multiple markets.
The company’s primary product categories include refrigerators and freezers, cooking appliances, dishwashers, washing machines and dryers. Through KitchenAid and other brands, Whirlpool also offers small domestic appliances and related products designed for food preparation and household use.
Whirlpool traces its history to 1911, when the Upton Machine Company began producing electric washing machines.
Read More Five stocks we like better than Whirlpool 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal 5 Retail Picks to Watch as the Holiday Shopping Season Nears Receive News & Ratings for Whirlpool Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whirlpool and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie GitLab v pondělí dosáhly nového 52týdenního maxima 56,64 USD poté, co společnost ve čtvrtletních výsledcích překonala odhady tržeb i zisku na akcii (EPS).
GitLab Inc. (NASDAQ:GTLB – Get Free Report)’s stock price reached a new 52-week high on Monday. The company traded as high as $56.64 and last traded at $55.9470, with a volume of 227,573 shares. The stock had previously closed at $55.09.
Wall Street Analysts Forecast Growth A number of research firms have commented on GTLB. Robert W. Baird raised their target price on shares of GitLab from $47.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. Bank of America increased their price objective on shares of GitLab from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Sanford C. Bernstein reiterated an “outperform” rating on shares of GitLab in a research note on Wednesday, September 2nd. TD Cowen boosted their price objective on shares of GitLab from $29.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, August 27th. Finally, Wells Fargo & Company upped their target price on GitLab from $40.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 2nd. Seven analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $51.75.
Check Out Our Latest Analysis on GTLB
GitLab Stock Up 1.7% The business has a 50-day moving average price of $45.74 and a 200-day moving average price of $33.54. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -175.08 and a beta of 0.98. GitLab (NASDAQ:GTLB – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.18 by $0.06. The firm had revenue of $286.25 million during the quarter, compared to analyst estimates of $273.13 million. GitLab had a negative return on equity of 1.28% and a negative net margin of 4.99%. The business’s revenue for the quarter was up 21.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS. GitLab has set its FY 2027 guidance at 0.850-0.870 EPS and its Q3 2027 guidance at 0.190-0.200 EPS. On average, equities research analysts forecast that GitLab Inc. will post -0.29 earnings per share for the current year.
Insider Activity at GitLab In related news, CTO Sivaprasad Padisetty sold 51,915 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $45.78, for a total value of $2,376,668.70. Following the completion of the transaction, the chief technology officer directly owned 377,211 shares of the company’s stock, valued at $17,268,719.58. This trade represents a 12.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Simon Mundy sold 8,725 shares of GitLab stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $38.00, for a total transaction of $331,550.00. Following the completion of the sale, the chief accounting officer owned 105,332 shares of the company’s stock, valued at $4,002,616. This trade represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,176,840 shares of company stock valued at $103,798,494 in the last three months. 10.64% of the stock is owned by insiders.
Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Atreides Management LP acquired a new stake in shares of GitLab in the second quarter valued at $102,983,000. SG Americas Securities LLC raised its holdings in shares of GitLab by 6,528.0% in the 1st quarter. SG Americas Securities LLC now owns 3,135,394 shares of the company’s stock valued at $67,850,000 after buying an additional 3,088,089 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in GitLab by 363.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,987,553 shares of the company’s stock worth $60,680,000 after acquiring an additional 1,558,625 shares in the last quarter. Light Street Capital Management LLC lifted its stake in GitLab by 66.2% during the 2nd quarter. Light Street Capital Management LLC now owns 1,945,000 shares of the company’s stock worth $59,381,000 after acquiring an additional 775,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in GitLab during the 1st quarter valued at about $16,074,000. Hedge funds and other institutional investors own 95.04% of the company’s stock.
About GitLab (Get Free Report)
GitLab Inc (NASDAQ:GTLB) develops a cloud-based DevSecOps platform that helps organizations plan, create, secure and deploy software. Its platform brings together source code management, version control, issue tracking, project planning, continuous integration and continuous delivery, enabling development, operations and security teams to collaborate in a unified environment.
GitLab’s products also include application security testing, vulnerability management, compliance tools, infrastructure as code, software supply chain security and monitoring capabilities.
Further Reading Five stocks we like better than GitLab 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal 5 Retail Picks to Watch as the Holiday Shopping Season Nears Receive News & Ratings for GitLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GitLab and related companies with MarketBeat.com's FREE daily email newsletter.
Společnost Teradyne rozšířila platformu Titan HP pro testování vysoce výkonných čipů pro AI; tržby divize Semi Test ve 2. čtvrtletí 2026 meziročně vzrostly o 128 %.
Key Takeaways Teradyne's enhanced Titan HP platform improves AI chip testing efficiency, reliability and cost optimization. TER's Semi Test revenues surged 128% in Q2 2026, while compute revenues jumped nearly 600% on AI demand. Teradyne shares surged 108% year to date, while its forward Price/Sales ratio of 10.77X exceeds the industry. Teradyne (TER - Free Report) is benefiting from robust demand for advanced semiconductor testing solutions, driven by accelerating AI data center investments, increasing chip complexity, and growing requirements for high-performance computing infrastructure. The company’s expanding test portfolio, particularly its latest Titan HP platform enhancements, strengthens its competitive position against KLA (KLAC - Free Report) and Cohu (COHU - Free Report) , which are also capitalizing on AI-driven semiconductor investments.
Teradyne recently introduced enhanced burn-in capabilities for its Titan HP platform, targeting high-power AI data center devices, automotive chips and other high-reliability semiconductors. The production-ready platform integrates reliability stress testing with system-level testing, enabling precise per-device thermal control under realistic workloads. Its asynchronous slot architecture allows independent testing, improving efficiency and reducing equipment downtime. Powered by Teradyne’s Atlas software, Titan HP enables manufacturers to streamline testing, reduce capital costs, optimize factory floor space and accelerate time to market. The platform is already deployed in production, strengthening Teradyne’s semiconductor testing portfolio across the AI device supply chain.
Teradyne’s strengthening position in AI-driven semiconductor testing is noteworthy. In the second quarter of 2026, Semi Test revenues surged 128% year over year, while compute revenues jumped nearly 600%, reflecting strong AI-related demand. Integrated Systems Test revenues increased 94% year over year to $67 million. The growing adoption of advanced packaging, AI accelerators and high-bandwidth memory is expected to drive demand for increasingly advanced testing solutions.
Teradyne’s robust AI test portfolio and strong customer traction are likely to strengthen its competitive position against KLA and Cohu. For the third quarter of 2026, Teradyne expects revenues in the range of $1.20-$1.30 billion.
How Competitors Fare Against TERTeradyne is facing stiff competition from companies such as KLA and Cohu. Both companies are expanding their footprint in the AI space.
KLA is benefiting from the growing demand for AI through its leadership in process control and its ability to address growth markets in wafer fab equipment, including high-bandwidth memory and advanced packaging.
In May 2026, Cohu received approximately $5 million in multiple orders for its Diamond X platform from a leading semiconductor manufacturer. The systems will support testing of next-generation GaN power devices for AI data centers, strengthening Cohu’s position in AI infrastructure and high-efficiency power semiconductor testing.
TER’s Share Price Performance, Valuation and EstimatesTeradyne shares have surged 108% year to date, outperforming the Zacks Computer & Technology sector’s 23.4% growth and the Zacks Electronics - Miscellaneous Products increase of 37.6%.
TER Stock Performance
Image Source: Zacks Investment Research
TER stock is trading at a premium with a forward 12-month Price/Sales of 10.77X compared with the Electronics - Miscellaneous Products industry’s 7.25X. TER has a Value Score of D.
TER Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for fiscal 2026 earnings is pegged at $9.11 per share, which has been unchanged over the past 30 days. This suggests 130.05% year-over-year growth.
Teradyne currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways Howmet's commercial aerospace revenues jumped 28% in Q2 2026, accounting for 53% of its total business.Engine Products revenues surged 32% to $1.37 billion, while Fastening Systems sales rose 37% to $589 million.Boeing and Airbus production trends and Howmet's $1.8 billion CAM acquisition bode well for future demand. Howmet Aerospace Inc. (HWM - Free Report) has been benefiting from strong momentum in the commercial aerospace market. Following year-over-year growth of 20% in first-quarter 2026, revenues from the commercial aerospace market increased 28% in the second quarter. The market constituted 53% of its overall business in the reported quarter.
This market strength significantly boosted Howmet’s Engine Products segment in the second quarter, which generated revenues of $1.37 billion, up 32% year over year. The top-line results were driven by robust demand for engine spares across commercial and defense aerospace markets, along with strength in the gas turbine market. Howmet’s Fastening Systems segment recorded revenues of $589 million, marking a 37% year-over-year increase, supported by solid demand in commercial and defense aerospace markets.
Boeing’s gradual production ramp-up, particularly for the 737 MAX narrowbody aircraft, is expected to sustain demand for Howmet in the coming quarters. Meanwhile, steady production rates for Airbus’ A320 narrowbody and A350 widebody aircraft also bode well for engine spare parts demand.
In April 2026, Howmet acquired Stanley Black & Decker, Inc.'s (SWK - Free Report) Consolidated Aerospace Manufacturing LLC (“CAM”) business for $1.8 billion. The acquisition, which strengthened HWM’s aerospace fastening solutions portfolio and engineering capabilities, is likely to increase its backlog conversion rate.
HWM’s Peers in the Commercial Aerospace MarketGE Aerospace (GE - Free Report) is benefiting from the solid demand for LEAP, GEnx & GE9X engines and services within the Commercial Engines & Services segment. In the second quarter of 2026, GE Aerospace’s engine deliveries within this segment increased 26% year over year, indicating better throughput as it works through customer demand. The Commercial Engines & Services segment’s revenues and orders jumped 27% and 18%, respectively, on a year-over-year basis in the quarter.
RTX Corporation (RTX - Free Report) reported 14.5% sales growth in the second quarter of 2026. This growth was driven by solid momentum in the commercial aerospace market, where RTX Corp. witnessed growth in aftermarket and OEM sales. An increase in commercial aerospace sales boosted RTX’s Collins Aerospace and Pratt & Whitney segments. Rising aircraft utilization and demand for sustainable technologies are supporting RTX Corp.’s growth.
HWM's Price Performance, Valuation and Estimates
Image Source: Zacks Investment Research
Shares of Howmet have gained 9.9% in the year-to-date period against the industry’s decline of 15.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, HWM is trading at a forward price-to-earnings ratio of 36.63X, above the industry’s average of 27.53X.
SummarySoFi is initiated at a 'Buy,' with fair value materially above current levels and a technical setup supportive of a year-end bounce.SOFI delivered strong Q2 results: $1.21 billion revenue (+41% YoY), record member/product growth, and raised FY 2026 revenue guidance to $4.75–$4.85 billion.Heavy reinvestment, not operational weakness, drove recent stock underperformance; management prioritizes long-term growth over near-term earnings or capital returns.Key risks include macro sensitivity, consumer credit exposure, intense fintech competition, and execution on growth initiatives; technical support holds near $15. Joe Hendrickson/iStock Editorial via Getty Images
The higher-for-longer theme has hurt many cyclical-value names. SoFi Technologies (SOFI) is among the laggards. Shares are down by more than 20% just since their late-August peak, as the benchmark 10-year Treasury rate has surged from below 4.7% to, at times, above 5.3%. Still, the San Francisco-based
9.82K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
SoFi Technologies spolu s Orbi a Mastercard spouštějí v Mexiku kartu umožňující platby kryptoměnami či fiat měnou; obchodníci po konverzi při platbě obdrží fiat měnu.
Key Takeaways SoFi Technologies, Orbi and Mastercard are launching cards that let Orbi users spend crypto or fiat balances.SoFi Tech Solutions will provide BIN sponsorship, card issuance, processing and compliance for Orbi.SoFi's MxDS link to support card purchases and ATM withdrawals; partners plan to explore SoFiUSD transfers. SoFi Technologies’ (SOFI - Free Report) business arm, SoFi Tech Solutions, has partnered with Mexican fintech Orbi and Mastercard to launch a crypto-linked card in Mexico. The program will allow Orbi customers to spend either traditional money or cryptocurrency balances wherever Mastercard is accepted, with merchants receiving fiat currency after conversion at checkout.
Under the agreement, SoFi Tech Solutions, formerly Galileo, will provide bank identification number (BIN) sponsorship alongside card issuance, transaction authorization, processing and compliance technology. Orbi will be its first cryptocurrency-focused customer under the Mastercard BIN sponsorship program in Mexico. Both physical and virtual cards will be supported.
SoFi Tech Solutions’ connection to Mastercard’s Mexico Domestic Switch (MxDS) will support card purchases and ATM withdrawals. The partners also plan to explore stablecoin-based cross-border transfers using SoFiUSD. Demand for dollar-linked stablecoins is growing in Latin America. Bitso said stablecoins accounted for 40% of its users’ crypto purchases across Mexico, Argentina, Brazil, and Colombia in 2025, compared with 18% for bitcoin.
The expansion follows SoFi’s September announcement that SoFiUSD settlement has gone live for SoFi Bank’s debit and credit card transactions on Mastercard's global payments network. SoFi Bank is migrating its entire card program to blockchain-based settlement using SoFiUSD. The stablecoin is redeemable one-for-one for U.S. dollars and backed by reserves consisting primarily of cash.
On the financial front, SoFi’s Technology Platform segment reported mixed results in the second quarter of 2026. The segment generated revenues of $84.5 million, down 23% year over year, although it increased 13% sequentially. The platform supported about 135 million accounts at quarter-end. While the partnership may not immediately reverse the segment’s revenue decline, it could support longer-term Tech Solutions growth.
How Are Competitors Faring?Robinhood Markets (HOOD - Free Report) is accelerating its cryptocurrency expansion through targeted acquisitions. In June 2026, it completed the purchase of Canada's WonderFi, gaining two regulated trading platforms and strengthening its position in Canada. The deal builds on its earlier Bitstamp acquisition, adding international scale. WonderFi's purchase consideration totaled approximately $178 million.
PayPal Holdings (PYPL - Free Report) is rapidly expanding its stablecoin ecosystem through strategic partnerships. In September 2026, it joined M0 and MoonPay to launch PYUSDx, enabling businesses to create customized stablecoins backed by PayPal USD. This initiative broadens PayPal's reach beyond consumer payments. The platform reported approximately $100 million in processed volume.
SOFI’s Price Performance, Valuation and EstimatesShares of SOFI have decreased 15.3% in the past three months, underperforming the broader industry and the S&P 500 Index.
Image Source: Zacks Investment Research
From a valuation standpoint, SOFI trades at a forward price-to-earnings ratio of 20.61X, well above the industry’s 15.15X. It carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for full-year 2026 EPS remained unchanged at 60 cents over the past two months.
Image Source: Zacks Investment Research
SOFI stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Nabídky AI společnosti FactSet ve 4. čtvrtletí fiskálního roku 2026 vytvořily více než 10 % nového ASV; volný peněžní tok vzrostl o více než 14 % na 707 mil. USD.
Key Takeaways FDS' AI offerings drove more than 10% of new ASV in fiscal Q4'26, with more than 650 clients engaged in MCP.AI-driven automation cut data processing times by over 75%, while fiscal 2026 FCF rose 14% to $707M.FDS faces rising AI competition, slowing ASV growth & margin pressures despite projected earnings growth.
FactSet’s (FDS - Free Report) expanding artificial intelligence (AI) capabilities and growing adoption of model context protocol (MCP) solutions are driving new revenue opportunities and deeper client engagement. Rising demand for AI-enabled data feeds and analytics supports cross-selling and long-term growth. Meanwhile, AI-driven automation, workforce optimization and organizational simplification are enhancing operating efficiency, while strengthening operating leverage, supporting margin expansion and driving sustained earnings and free cash flow growth.
The company’s first-quarter fiscal 2027 earnings are expected to increase 11.1% year over year. Its fiscal 2027 and 2028 earnings are projected to rise 9% and 10.5%, respectively. Revenues are anticipated to grow 5.8% in fiscal 2027 and fiscal 2028.
Factors That Bodes Well for FDS’ SuccessAI Adoption & Expanding Data Drive Long-Term Growth: FactSet's expanding AI capabilities are creating new revenue opportunities and deepening client relationships. In fourth-quarter fiscal 2026, AI-enabled offerings contributed more than 10% of new annual subscription value (ASV). More than 650 clients were engaged in MCP contracts or trials at fiscal year-end, while MCP application programming interface (API) call volumes surged sevenfold sequentially. Clients adopting AI solutions recorded ASV growth at twice the rate of the broader client base, highlighting rising demand and cross-selling opportunities. Moreover, double-digit growth in data ASV reflects increasing adoption of direct feeds, APIs and AI-driven delivery channels. Continued integration of AI into financial workflows should support sustained client expansion and long-term revenue growth.
AI-Driven Efficiency Supports Margin Expansion: FactSet's organizational restructuring and AI-driven automation are enhancing operating efficiency and creating capacity for growth investments. In fiscal 2026, the company reduced headcount and expanded AI-assisted engineering initiatives to streamline operations. Automation reduced private markets data processing times by more than 75%, while its client assistance agent now resolves more than 30% of user requests without human intervention.
The shift toward a unified product organization and lower operating complexity should further improve cost efficiency. Continued automation and disciplined resource allocation are expected to strengthen operating leverage, supporting sustained margin expansion, earnings growth and free cash flow generation.
Free Cash Flow & Shareholder Returns Aid Long-Term Value: FactSet's sustained cash generation supports higher shareholder distributions and financial flexibility. Free cash flow increased from $584.8 million in fiscal 2023 to $614.7 million in fiscal 2024 and $617.5 million in fiscal 2025. In fiscal 2026, free cash flow rose more than 14% to $707 million, including $177 million in the fourth quarter despite restructuring costs. Share repurchases more than doubled to $644 million, reducing shares outstanding by nearly 7%. Total capital returned through dividends and buybacks exceeded $800 million, up more than 75% year over year. Rising cash generation and disciplined capital allocation should sustain shareholder returns while providing capacity for strategic investments and long-term earnings growth.
Watch Out for These Risks to FDS StockRising AI Competition & Pricing Uncertainty: FactSet faces increasing competition as financial data providers and AI platforms expand their MCP-enabled offerings. The shift toward agent-driven workflows could weaken demand for traditional workstations and reduce pricing power. Meanwhile, growing reliance on consumption-based pricing introduces revenue variability and reduces visibility into forecasts. AI monetization remains in its early stages, with adoption varying across clients. Intensifying competition and evolving customer preferences could constrain client expansion, limit pricing flexibility and slow revenue growth. These uncertainties may challenge FactSet's ability to sustain predictable long-term growth despite increasing AI adoption.
Margin Pressure & Slowing Growth Threaten Earnings: FactSet's infrastructure, cybersecurity and product investments weighed on fiscal 2026 profitability, with adjusted operating margin contracting 180 basis points to 34.5%. Higher incentive compensation recognized ahead of associated revenues added to margin pressure. Management expects organic ASV growth to moderate to 5-6.5% in fiscal 2027 from 7% in fiscal 2026. Higher taxes and refinancing costs on $500 million of notes maturing in March 2027 are expected to reduce EPS growth by approximately two percentage points. Despite a projected 25-75 basis-point margin recovery, slower growth and continued investment needs could constrain earnings expansion. Delays in realizing productivity gains may further limit profitability improvement.
FDS’ Zacks Rank & Stocks to ConsiderFactSet currently carries a Zacks Rank #3 (Hold) at present.
A couple of better-ranked stocks in the broader Business Services sector are The GEO Group, Inc. (GEO - Free Report) and GFL Environmental Inc. (GFL - Free Report) .
The GEO Group carries a Zacks Rank #2 (Buy) at present. It has a long-term earnings growth expectation of 14%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GEO beat earnings estimates in three of the trailing four quarters and matched once, delivering an earnings surprise of 24.6%, on average.
GFL Environmental also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 23.6%.
GFL beat earnings estimates in two of the trailing four quarters and missed twice, with an average earnings surprise of 19.4%.
Shares of Dream Finders Homes, Inc. (NYSE:DFH – Get Free Report) hit a new 52-week low during trading on Monday. The company traded as low as $9.10 and last traded at $9.15, with a volume of 32,548 shares. The stock had previously closed at $9.38.
Wall Street Analyst Weigh In Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Dream Finders Homes in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Dream Finders Homes presently has a consensus rating of “Hold”.
Check Out Our Latest Report on DFH
Dream Finders Homes Stock Down 1.6% The company has a market cap of $837.35 million, a P/E ratio of 6.46 and a beta of 1.91. The company has a fifty day moving average of $12.91 and a 200 day moving average of $14.19. Dream Finders Homes (NYSE:DFH – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.27 earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. Dream Finders Homes had a return on equity of 10.38% and a net margin of 3.55%.
Insider Activity at Dream Finders Homes In other Dream Finders Homes news, Director Richard Beckwitt acquired 10,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were purchased at an average price of $12.07 per share, for a total transaction of $120,700.00. Following the purchase, the director directly owned 100,000 shares of the company’s stock, valued at approximately $1,207,000. This trade represents a 11.11% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 103,000 shares of company stock worth $1,427,755. 65.97% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Dream Finders Homes A number of institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP purchased a new stake in Dream Finders Homes during the second quarter valued at approximately $667,000. Bank of New York Mellon Corp purchased a new position in shares of Dream Finders Homes during the 2nd quarter worth $2,833,000. Handelsbanken Fonder AB boosted its stake in shares of Dream Finders Homes by 87.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $459,000 after acquiring an additional 12,400 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Dream Finders Homes by 37.5% during the 2nd quarter. GAMMA Investing LLC now owns 9,996 shares of the company’s stock worth $173,000 after acquiring an additional 2,728 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Dream Finders Homes by 59.4% during the 2nd quarter. Versant Capital Management Inc now owns 5,135 shares of the company’s stock valued at $89,000 after acquiring an additional 1,913 shares during the period. Hedge funds and other institutional investors own 95.55% of the company’s stock.
(Get Free Report)
Dream Finders Homes, Inc is a residential homebuilder that designs, constructs and sells single-family homes. The company offers a range of home plans and options intended for first-time, move-up and luxury buyers, with homes typically sold through a build-to-order model as well as from completed inventory. Its operations also include the development and acquisition of residential lots for use in its homebuilding activities.
Founded in 2008, Dream Finders Homes has expanded through organic growth and acquisitions into multiple housing markets across the United States.
Read More Five stocks we like better than Dream Finders Homes 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal 5 Retail Picks to Watch as the Holiday Shopping Season Nears Receive News & Ratings for Dream Finders Homes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dream Finders Homes and related companies with MarketBeat.com's FREE daily email newsletter.
Tržby Ralph Lauren v Číně v 1. čtvrtletí fiskálního roku 2027 vzrostly při konstantních měnových kurzech o více než 40 %. Firma pro celý rok očekává růst v řádu středních nácti procent.
Key Takeaways RL's China sales rose more than 40% in fiscal first-quarter 2027 on a constant-currency basis.RL's first Beijing Polo match reached 74 million livestream viewers as Greater China grew to 10% of sales.RL expects mid-teens China growth in fiscal 2027, with low-double-digit growth over its three-year plan.
Ralph Lauren Corporation (RL - Free Report) delivered strong growth in China in the first quarter of fiscal 2027, with sales rising more than 40% on a constant-currency basis. However, management expects growth to moderate as the company faces tougher comparisons in the second half of the fiscal year. Its brand-building initiatives, selective retail expansion and consumer engagement efforts remain central to its China strategy.
China's performance benefited from global marketing campaigns and localized brand activations. The company's first-ever Polo match in Beijing reached 74 million livestream viewers, highlighting the scale of engagement generated by the event. Ralph Lauren is also concentrating on six key Chinese city clusters, with a disciplined retail rollout and continued investment in digital channels. Management said Greater China's share of the company had risen to 10%.
Product demand offers another source of opportunity. Management described the core business in China as strong, with the women's business and handbags delivering disproportionate performance. Globally, women's apparel, outerwear and handbags collectively grew more than 20% in the quarter, outpacing total company growth.
Nevertheless, management does not expect China's recent growth rate to continue at the same pace every quarter. It anticipates mid-teens sales growth in China for fiscal 2027, citing particularly strong comparisons in the second half. Over its three-year Drive strategic plan, the company continues to target low-double-digit growth in China. The broader Asian business also delivered strong results. Regional revenues increased 25% on a constant-currency basis in the fiscal first quarter, while Japan and Korea recorded double-digit growth.
Overall, Ralph Lauren's China business has benefited from brand activations, customer engagement and a focused market strategy. Although the latest growth rate may not be repeated each quarter, management's mid-teens outlook for fiscal 2027 and low-double-digit target over its three-year plan indicate its expectations for continued growth at a more moderate pace.
The Zacks Rundown for RLThis Zacks Rank #3 (Hold) company’s shares have lost 1.5% in the past six months compared with the industry’s 4.3% decline.
Image Source: Zacks Investment Research
From a valuation standpoint, RL trades at a forward price-to-earnings ratio of 18.71 compared with the industry’s average of 15.09.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for RL’s current and next fiscal-year earnings implies a rise of 13.3% and 10.6%, respectively, from the year-ago figures.
Image Source: Zacks Investment Research
Stocks to ConsiderSome better-ranked stocks have been discussed below:
Vince Holding Corp. (VNCE - Free Report) provides luxury apparel and accessories in the United States and internationally. It operates through Vince Wholesale and Vince Direct-to-Consumer segments. At present, the company carries a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for VNCE’s current fiscal-year sales and earnings implies growth of 14.3% and 175%, respectively, from the year-ago reported figures. VNCE has delivered a trailing four-quarter earnings surprise of 561.4%, on average.
Kontoor Brands, Inc. (KTB - Free Report) , a lifestyle apparel company, designs, manufactures, procures, sells and licenses apparel, footwear and accessories, primarily under the Wrangler, Lee and Helly Hansen brands. At present, KTB carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for KTB’s current fiscal-year sales and earnings implies a decline of 14.3% and 6.1%, respectively, from the year-ago figures. KTB delivered a trailing four-quarter earnings surprise of 21.4%, on average.
G-III Apparel Group, Ltd. (GIII - Free Report) designs, sources, and markets women's and men's apparel in the United States and internationally. GIII currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for GIII’s current financial-year sales and earnings is expected to decline 8.4% and 13.8%, respectively, from the corresponding year-ago reported figures. GIII delivered a trailing four-quarter negative earnings surprise of 1.4%, on average.
Nu Holdings ve druhém čtvrtletí 2026 dosáhla čtvrtletního čistého zisku přes 1 mld. USD, což při konstantních měnových kurzech představuje meziroční nárůst o 49 %. Tržby vzrostly o 39 % na 5,9 mld. USD.
Nu Holdings (NU -0.43%) has reached a milestone that would have seemed almost impossible when it launched in 2013. The company just generated more than $1 billion in quarterly net income in the second quarter of 2026, up 49% year over year on a foreign-exchange-neutral basis. Revenue also climbed 39% to $5.9 billion.
While this milestone is important, investors shouldn't focus on the $1 billion figure alone. The more important thing is what this milestone tells us about the business and its future.
Image source: Getty Images.
The business is reaching a different scale
For years, the Nu Holdings story was primarily about customer growth, and there was plenty of it. The company added roughly 4 million customers during Q2, bringing its total to 139 million across Brazil, Mexico, and Colombia.
But Nu Holdings is no longer simply adding customers and hoping they eventually become profitable. It is increasingly monetizing its existing customers. Monthly average revenue per active customer, or ARPAC, reached approximately $17 in Q2. That figure has been rising quarter after quarter, up from just $8 in the same period in 2022. This is an important development.
A digital bank becomes much more valuable when customers stop treating it as an extra financial app and start using it as their primary banking facility. Once that happens, Nu Holdings has more opportunities to earn revenue from the same customer. That is how customer growth can eventually turn into much larger earnings growth.
Premium Feature
Moneyball Superscore
84/100
Today's Change
(
-0.43
%) $
-0.07
Current Price
$
16.05
The bigger opportunity is earning more from each customer
That brings us to the most important part of the $1 billion milestone. Nu Holdings doesn't necessarily need another 100 million customers to dramatically increase its profits. It can deepen its relationship with its existing 139 million customers.
Consider what happens if a customer who once used Nubank primarily for a credit card begins to keep their salary there, pay bills through the platform, hold savings, take a loan, and eventually use investment products. The customer count hasn't changed, but the economic value of that customer has.
Besides, ARPAC growth doesn't tell the whole story, since it's a mix of more mature markets like Brazil and newer markets like Mexico. As the latter market matures, the ARPAC will expand further.
In other words, Nu Holdings runs a business that gets better over time. More customers create a larger base to sell products to, while more products increase revenue per customer. Moreover, a larger revenue base can spread Nu Holdings' technology and operating costs across more customers.
The real question is what happens after $1 billion
$1 billion might be a milestone worth celebrating, but investors should not get carried away. A $1 billion quarterly profit doesn't automatically mean Nu Holdings can generate $4 billion every year indefinitely. Banking earnings can fluctuate, particularly when credit losses change.
For perspective, the 90-plus-day non-performing loans reached 6.9% in Q2, up from 5.8% in Q2 2023. However , this isn't a simple three-year upward trend. The ratio has fluctuated over time, and it reached around 7% in the third quarter of 2024 before declining.
That's an important distinction. The concern isn't that Nu Holdings' credit quality is suddenly deteriorating. Rather, investors need to watch whether the company can maintain its strong profitability as it takes on more credit risk and expands its balance sheet.
If Nu Holdings can continue growing its loan book, increasing revenue per customer, and maintaining strong credit discipline, its earnings power could continue expanding.
What does it mean for investors?
Nu Holdings' first $1 billion quarterly profit is an impressive milestone. But for long-term investors, the number itself isn't the investment thesis. The real opportunity lies in what comes next.
The bank now has 139 million customers, rising revenue per customer, and a rapidly growing financial ecosystem. If it can continue deepening relationships while maintaining credit discipline, today's $1 billion quarterly profit could eventually look like the beginning, rather than the end, of its earnings story.
The most important thing is whether the company can sustain and compound its profitability as it becomes a much larger bank. That's what investors should watch going forward.
Nu Holdings dosáhla ve druhém čtvrtletí 2026 čistého zisku 1,1 mld. USD; ARPAC vzrostl na 17 USD, návratnost vlastního kapitálu (ROE) činila 33 %, zatímco podíl úvěrů po splatnosti déle než 90 dní dosáhl 6,9 %.
Nu Holdings (NU -0.50%) has become one of the most interesting financial companies in the world. The digital bank now serves nearly 139 million customers across Brazil, Mexico, and Colombia. In the second quarter of 2026, it generated $1.1 billion in net income, its first quarterly profit above $1 billion.
But investors don't need to follow dozens of financial metrics to understand whether the business is moving in the right direction. If I could track just three numbers, they would be average revenue per active customer (ARPAC), return on equity, and credit quality.
Together, they tell us whether Nu Holdings is making its customers more valuable, generating attractive returns, and keeping its biggest risk under control.
Image source: Getty Images.
1. Average revenue per active customer (ARPAC)
In simple terms, ARPAC indicates how much revenue Nu Holdings generates per active customer per month. In the second quarter, ARPAC reached approximately $17, up from $13 a year earlier and roughly $8 in the second quarter of 2022. Why does this matter?
Well, imagine Nu Holdings has 100 customers. If each customer generates only $5 of monthly revenue, adding more customers is helpful. But the economics become much more interesting if those same customers eventually generate $10 or $15 in revenue, since the company can save on customer acquisition costs.
That is what makes ARPAC so important. Nu Holdings doesn't necessarily need another 100 million customers to significantly grow its earnings. It can also increase revenue from its existing customers and gain operating leverage.
In other words, as customers become more active and adopt additional products -- such as loans, savings, payments, and investments -- their economic value will increase. For investors, I'd watch whether ARPAC continues to rise over the next several years.
Premium Feature
Moneyball Superscore
84/100
Today's Change
(
-0.50
%) $
-0.08
Current Price
$
16.04
2. Return on equity (ROE)
The second number is return on equity (ROE). This sounds complicated, but the basic idea is simple: A bank needs shareholders' capital to operate. ROE tells us how much profit the company generates relative to the capital it uses. Think of it as a measure of how efficiently management is using shareholders' money.
Nu Holdings generated a 33% ROE in the second quarter (annualized), up from 28% a year earlier. That is important because rapid growth by itself isn't necessarily valuable. A company could double its loan book and revenue while requiring substantial additional capital. If returns remain low, shareholders may not benefit much.
Nu is showing something different. It is growing rapidly while currently generating very high returns on capital. The question now is whether Nu Holdings can maintain an attractive ROE as the business grows significantly over the next few years.
3. 90+ non-performing loan (NPL) ratio
The third number is the least exciting, but potentially the most important. It is the percentage of loans that are more than 90 days past due, known as the 90+ non-performing loan, or NPL, ratio.
Why should investors care? Because lending is one of Nu's biggest businesses. Its credit portfolio reached $39.4 billion in the second quarter of 2026, up from $27.3 billion a year earlier. When a bank lends money, some customers inevitably don't repay their loans. If those losses become too large, they can wipe out a significant portion of the profits generated by lending.
Nu Holdings' 90+ NPL ratio was 6.9% in the second quarter, compared with 6.5% in the first quarter. The company said the quarterly increase largely reflected the seasonal migration of earlier delinquencies. The faster Nu Holdings grows its lending business, the more important it becomes to prove that it can control credit losses. That's why 90+ NPL ratio is a number worth watching closely.
What does it mean for investors?
ARPAC tells us whether customers are becoming more valuable. ROE tells us whether Nu Holdings is turning capital into profits efficiently. 90+ NPL ratio tells us how much credit risk sits behind those profits. We want the first two numbers to remain strong while the third stays under control.
This is particularly important, as the company has already proven that it can attract customers at an extraordinary scale. Now investors need to see whether it can continue to make those customers more valuable without taking excessive credit risk.
If it can, the $1 billion quarterly profit milestone may eventually look much less impressive than what comes next.
Domino’s Pizza před zveřejněním výsledků za třetí čtvrtletí očekává tržby ve výši 1,18 miliardy USD a zisk na akcii (EPS) 4,37 USD, a to po třech po sobě jdoucích nesplněních odhadů zisku na akcii.
Restaurant company Domino’s Pizza (NASDAQ:DPZ) has struggled in 2026, with shares trading near their five-year lows that were hit back in June. The company reports third-quarter financial results Tuesday before the market open.
Here’s a look at the earnings estimates, analyst ratings and key items to watch.
• Domino’s Pizza shares are advancing steadily. Why are DPZ shares climbing?
Domino’s Pizza Q3 Earnings EstimatesAnalysts expect Domino’s Pizza to report third-quarter revenue of $1.18 billion, up from $1.15 billion in last year’s third quarter, according to data from Benzinga Pro.
The company has beaten analyst estimates for revenue in five of the last 10 quarters overall, including the most recently reported second quarter.
Analysts expect Domino’s Pizza to report third-quarter earnings per share of $4.37, up from $4.08 in last year’s third quarter.
The company has missed analyst estimates for earnings per share in three straight quarters and in five of the last 10 quarters overall.
Read Next
Domino’s Pizza Analyst RatingsAnalysts have been lowering their price targets on Domino’s Pizza ahead of the upcoming earnings. Here are some of the latest analyst ratings and price targets on Domino’s Pizza stock.
RBC Capital: Maintained Sector Perform rating, lowered price target from $350 to $325 JPMorgan: Maintained Overweight rating, lowered price target from $380 to $350 Guggenheim: Maintained Neutral rating, lowered price target from 440 to $325 Seaport Global: Initiated with Neutral rating, no price target Key Items to WatchAs shown above, revenue and earnings have been a mixed bag for the pizza chain, with analyst beats in five of the last 10 quarters for each of revenue and earnings per share.
In the second quarter, revenue was up 4.3% year-over-year, while earnings per share missed analyst estimates.
Among the areas for investors and analysts to watch will be sales by region. U.S. retail sales were up 1.9% year-over-year in the second quarter, with international sales up 4.1% year-over-year. With same-store sales for both regions essentially flat, the growth came from new stores.
In the second quarter, Domino’s opened 26 stores in the U.S. and 183 internationally. Investors will be closely monitoring how many new stores were opened and company guidance for new store opening going forward.
Domino’s also kicked off this month with new CEO Joe Jordan, who previously served as the company’s chief operating officer and president of Domino’s U.S. Investors could get a better idea on what Jordan’s focus areas will be moving forward.
Less important to investors, it’s worth noting that Domino’s Pizza may have been a battleground stock for former Berkshire Hathaway (NYSE:BRK)(NYSE:BRK) CEO Warren Buffett and his successor Greg Abel. Domino’s was the 20th largest stock holding for the conglomerate in the fourth quarter of 2025, with the stake increased several times.
In the first quarter of 2026, the first with Abel as CEO, the position in Domino’s Pizza went to 0, with 3,350,000 shares sold.
Domino’s stock has underperformed the market since, making Abel’s sale look like the right move
Domino’s Stock Price ActionDomino’s stock is up 0.59% to $311.18 on Monday versus a 52-week trading range of $282 to $442.35. Domino’s stock is down 26.8% year-to-date in 2026.
Kahn Swick & Foti vyšetřuje vedení společnosti SoundHound AI kvůli možnému porušení fiduciárních povinností po přepracování části účetních výkazů za rok 2024.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into SoundHound AI, Inc. (NasdaqGM: SOUN) (“SoundHound” or the “Company”).
In January 2024, the Company acquired artificial intelligence (“AI”) software companies SYNQ3 and Amelia Holdings, Inc., resulting in what it hailed as the Company’s “breakthrough year” in 2024. However, on March 4, 2025, the Company disclosed it could not timely file its 2024 Annual Report “[d]ue to the complexity of accounting for [the SYNQ3 and Amelia Acquisitions]” and that it “ha[d] identified material weaknesses in its internal control over financial reporting.” A week later, the Company filed its 2024 10-K, which restated certain financials and revealed for the first time that the Company’s lack of effective controls was impairing its ability to account for corporate acquisitions.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.
KSF’s investigation is focusing on whether SoundHound’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of SoundHound shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-soun/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Key Takeaways TEM expands collaborations to strengthen its precision medicine presence and drive future revenue growth.
TEM's expanded collaboration supports potential commercialization of Moderna and Merck's cancer therapy.
Tempus extends its Recursion data deal through 2029, securing $42M in payments and access to its RNA model.
Tempus AI (TEM - Free Report) is expanding its presence in precision medicine through collaborations, which may support future revenue growth. In line with this, Tempus entered an expanded multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy developed by Moderna and Merck and evaluated with KEYTRUDA in patients with resected stage IIB-IV melanoma and other cancers. Under the collaboration, Tempus will coordinate the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and, subject to regulatory approvals, provide NGS services to support therapy design and manufacturing.
Tempus extended its data partnership with Recursion Pharmaceuticals, Inc. (RXRX - Free Report) through November 2029. As part of the extension, the companies amended the original agreement’s annual license fees, replacing discretionary payments of up to $84 million over the next two years with committed payments totaling $42 million over the next three years. Under a separate agreement, Recursion also granted Tempus a non-exclusive, worldwide license to its proprietary RNA Foundation Model, TxFM.
Tempus partnered with Angiosarcoma Awareness, Inc. to advance data-driven research into angiosarcoma, a rare and aggressive cancer. The collaboration will leverage Tempus’ analytical resources and approximately 600 de-identified patient records with paired DNA and RNA sequencing data and available clinical information to deepen understanding of the disease.
Peer UpdateDoximity (DOCS - Free Report) announced an integration with Aledade, a physician-led leader in value-based care. The agreement will integrate Doximity’s HIPAA-compliant Clinical AI Suite, including its Scribe ambient notetaking tool and Ask clinical AI assistant, into Aledade Assist, an EHR overlay that provides clinical insights at the point of care.
Natera (NTRA - Free Report) entered a national partnership with Susan G. Komen, the world’s leading breast cancer organization. Together, the companies aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera will serve as the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure and MORE THAN PINK Walk events. Through this, Natera will help raise awareness of breast health, support patients and survivors and advance Komen’s mission to save lives.
TEM’s Stock Price PerformanceIn the past year, Tempus’ shares have lost 24.9% compared with the industry’s 5.7% decline.
Image Source: Zacks Investment Research
Expensive ValuationTEM currently trades at a forward 12-month Price-to-Sales (P/S) of 6.73X compared with the industry average of 4.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate TrendIn the past 30 days, Tempus’ loss per share estimate for 2026 has remained unchanged.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ARK Invest navzdory letošní stagnaci či poklesu Bitcoinu nadále zastává pětiletou investiční tezi a považuje jej za digitální zlato i peníze bez nutnosti povolení.
ARK Invest holds its 5-year Bitcoin thesis despite a flat year. Lorenzo Valente breaks down its Big Ideas report, digital gold, and institutional adoption.
Bitcoin has been flat to down this year, but ARK Invest isn’t changing its view. Lorenzo Valente, Director of Research for Digital Assets at ARK Invest, explains why the firm looks at Bitcoin on a five-year horizon and still believes it’s very early in the Bitcoin journey. He discusses ARK’s Big Ideas report, Bitcoin’s role as digital gold and permissionless money, and what still keeps institutional money on the sidelines.
Chapters:
0:00 – ARK Invest’s Lorenzo Valente on How Wall Street Sees Bitcoin Now
1:36 – ARK’s Big Ideas Bitcoin Price Target for 2030
2:51 – How Stablecoins Changed ARK’s Emerging Market Bitcoin Thesis
4:53 – The Rise of Tokenized Stocks and Real-World Assets
7:13 – What Tokenized Stocks Can Do That Brokerage Accounts Can’t
9:35 – Higher Rates, Inflation, AI and Bitcoin’s Macro Outlook
12:49 – Which Tokenization Business Models Will Win?
15:41 – Exporting U.S. Assets Offshore Through Tokenization
17:34 – ARK’s Bitcoin Outlook for the Next 12 to 18 Months
18:29 – The Four-Year Cycle and What to Watch Next
DISCLAIMER: The views and opinions expressed in this show are those of the participants and do not necessarily reflect the official policy or position of BTC Inc., Bitcoin Magazine, or any affiliated entities. This content is provided for informational and educational purposes only and should not be construed as investment, legal, tax, or accounting advice. Nothing contained in this show constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or financial instruments. Viewers should consult their own advisors before making financial or business decisions.
Patrick Green
Patrick Green is an Assistant Producer and Channel Manager on the multimedia team at Bitcoin Magazine, focusing on production, content distribution, and channel strategy across the network.
Rigetti má u 108qubitového systému Cepheus dobu koherence pouhých přibližně 25 až 30 mikrosekund, což omezuje spolehlivost výpočtů. Úpravy čipů a materiálů by ji mohly během několika let zdvojnásobit až ztrojnásobit.
Key Takeaways Rigetti's 108-qubit Cepheus system faces coherence limits of 25-30 microseconds.Chip redesigns, fabrication upgrades and materials innovations could triple Rigetti's coherence times.RGTI is exploring tantalum-capped superconducting contacts to improve system performance.
Rigetti Computing (RGTI - Free Report) is shifting its focus toward improving quantum processor quality as it works to advance its next-generation computing systems. During its second-quarter 2026 earnings call, management identified coherence time as the primary technical hurdle affecting two-qubit gate fidelity in its flagship 108-qubit Cepheus system. Although Cepheus-1-108Q ranks among a limited group of generally available gate-based quantum computers with more than 100 qubits, its coherence times of approximately 25-30 microseconds continue to constrain computational reliability. This highlights a key challenge for Rigetti as it seeks to translate higher qubit counts into meaningful improvements in quantum processing capabilities.
To address these limitations, Rigetti is pursuing a combination of chip redesigns, fabrication process enhancements and materials innovations. The company is also exploring tantalum-capped superconducting contacts to help mitigate performance degradation. Management expects these efforts to potentially double or triple coherence times over the next several years, which could improve two-qubit gate fidelity and strengthen overall system performance. However, achieving these gains will depend on the successful execution of its engineering initiatives and the consistency of improvements across its quantum processors.
The progress of these initiatives will be an important factor in determining Rigetti's ability to advance toward larger and more commercially viable quantum systems. While increasing qubit capacity remains an important part of its technology roadmap, sustained improvements in coherence and gate performance will be essential to making quantum computing more reliable for practical applications. Investors will be watching whether Rigetti can deliver measurable performance gains alongside its ongoing efforts to scale its systems.
Peers UpdatesIonQ (IONQ - Free Report) recently signed an $8.18 million commercial agreement with Congruity360 to integrate quantum-safe networking capabilities into the latter’s enterprise data management platform. Under the agreement, Congruity360 will deploy IonQ’s post-quantum cryptography and quantum key distribution appliances to strengthen protection for sensitive enterprise data across its U.S. client base.
The companies described the agreement as one of the largest commercial quantum security deals announced in the United States, highlighting growing interest in next-generation cybersecurity solutions. The contract could help IonQ expand its commercial presence in quantum security and capitalize on enterprise demand for infrastructure designed to address emerging quantum-related cybersecurity risks.
Quantum Computing Inc. (QUBT - Free Report) recently entered into a three-year Framework Agreement with Hamad Bin Khalifa University in Qatar to advance collaborative initiatives spanning quantum computing, sensing and communications. The agreement covers joint research, executive education, industry-oriented projects, quantum application development and co-marketing activities designed to promote broader adoption of quantum technologies in Qatar and other markets.
The collaboration also aims to develop practical quantum-based solutions for real-world challenges while strengthening the regional talent pipeline. The partnership could expand QUBT’s academic and industry engagement, creating opportunities to advance application development and build awareness of its quantum technology offerings.
Rigetti’s Price Performance, Valuation and EstimatesShares of RGTI have lost 36.7% in the year-to-date period against the industry’s growth of 9.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, Rigetti trades at a price-to-book ratio of 8.71, above the industry average. RGTI carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Rigetti’s 2026 earnings implies a significant 70.3% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways NVTS and Microchip developed an 800V-to-6V reference design with up to 96% peak efficiency.The design delivers 2,100 watts per cubic inch using NVTS' GaN devices and Microchip's digital controls.NVTS' high-power markets grew over 50% year over year in the second quarter of 2026. Navitas Semiconductor (NVTS - Free Report) is expanding its AI data center opportunity through its collaboration with Microchip Technology. The companies have developed an 800V DC-to-6V DC reference design for next-generation AI data center racks. The solution combines Microchip’s digital power control and security technologies with NVTS’ GaN power devices and is aligned with the Open Compute Project’s 800V DC standard. The reference design includes hardware, software and design documentation to help data center developers reduce design time and bring new power systems to market faster.
The reference design uses NVTS’ 650V GaNFast FETs and Microchip’s dsPIC33AK digital signal controllers and TA100 CryptoAuthentication device. The system is designed to deliver up to 96% peak efficiency at full load, with a power density of 2,100 watts per cubic inch. It directly converts 800V DC to 6V DC by combining the 800V-to-50V and 50V-to-6V stages into a single converter. This approach is aimed at improving power conversion efficiency while supporting compact rack power systems.
The collaboration comes as AI data centers require higher power density and more efficient power delivery. Navitas has been focusing on this market as part of its broader shift toward high-power applications. In the second quarter of 2026, NVTS’ high-power markets grew more than 50% year over year, while AI infrastructure is expected to account for more than one-third of total sales by the end of 2026. The company is also working on multiple AI data center programs tied to the transition toward 800V architectures.
The Microchip collaboration could help NVTS strengthen its position as more data center operators adopt 800V power systems. By combining NVTS’ GaN technology with Microchip’s digital control and security capabilities, the companies are offering customers a more complete solution for AI rack power. As 800V adoption expands, the new reference design could help NVTS gain additional design opportunities in the growing AI data center market.
How Competitors Fare Against NVTSThe company faces strong competition from ON Semiconductor (ON - Free Report) and STMicroelectronics (STM - Free Report) in the race to supply high-voltage solutions for AI data centers.
ON is expanding its presence in AI data center power as the industry moves toward 800V DC architectures. The company expects AI data center revenues to more than double in 2026, while silicon carbide revenues from AI data center applications are expected to grow nearly 60% year over year. The company expects its high-voltage revenues to accelerate as data centers adopt 800V DC distribution, increasing demand for its power solutions across the AI power tree.
STMicroelectronics is another semiconductor company gaining from rising AI data center power demand. The company reported 50% year-over-year growth in communication equipment and computer peripherals in the second quarter, supported by its AI-related customer programs. STM is already supplying microcontrollers, high-voltage power and analog products for the power stage of cloud AI systems and is building a pipeline for low-voltage power solutions. The company expects data center revenues to exceed $1 billion in 2026 and $2 billion in 2027 if current trends continue.
NVTS' Price Performance, Valuation & EstimatesShares of Navitas Semiconductor have rallied 51% year to date compared with the Zacks Electronics – Semiconductors industry’s growth of 31%.
NVTS YTD Price Return Performance
Image Source: Zacks Investment Research
From a valuation standpoint, Navitas Semiconductor trades at a forward price-to-sales ratio of 43.71X, significantly higher than the industry’s average of 4.91X. The Zacks Value Score of F suggests that NVTS stock is overvalued.
NVTS Forward 12-Month P/S Ratio
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Navitas Semiconductor’s 2026 bottom line is pegged at a loss of 14 cents per share. The estimates for 2026 loss per share have remained unchanged over the past 30 days.
Image Source: Zacks Investment Research
Navitas Semiconductor currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways Shell is acquiring a 30% interest from EQNR in Bay du Nord, expanding its Canadian offshore presence.Bay du Nord holds over 400 million barrels of recoverable resources, with first oil anticipated in 2031.The C$14 billion project targets an early 2027 investment decision, subject to approvals and return criteria.
Shell plc (SHEL - Free Report) is expanding its presence in Canada’s offshore energy sector through an agreement to acquire a 30% non-operated interest in the proposed Bay du Nord oil project from Equinor ASA (EQNR - Free Report) . The transaction offers Shell exposure to an established resource base with potential for long-term growth, aligning with its disciplined approach to portfolio development and capital allocation. The deal also reinforces Shell’s position in Canada, where it already has significant natural gas, LNG and downstream operations.
Bay du Nord Deal Offers Long-Term Growth PotentialLocated in the Flemish Pass Basin, approximately 500 kilometers offshore Newfoundland and Labrador, Bay du Nord is a proposed deepwater oil development with substantial resource potential. Shell views the transaction as an attractive entry point, with expected returns above its investment hurdle rate.
The initial development phase includes the Bay du Nord and Cambriol discoveries, with estimated recoverable resources exceeding 400 million barrels of oil. The project also offers potential for future subsea tiebacks from nearby discoveries, including Cappahayden, Harpoon and Baccalieu. These opportunities could provide additional avenues for growth as the broader basin is developed.
Phased Development Supports Project FlexibilityBay du Nord is planned as a phased subsea development connected to a floating production, storage and offloading (FPSO) vessel. The project is designed for a gross production capacity of 160,000-175,000 barrels of oil equivalent per day, with first oil anticipated in 2031.
The estimated investment required for the development is approximately C$14 billion. Equinor will retain a 70% interest and continue as the project operator, while Shell will participate as a non-operating partner. The partnership structure allows Shell to gain exposure to the project's potential without taking the lead operating role.
Investment Decision Remains a Key MilestoneBay du Nord remains in the pre-final investment decision (FID) stage, with an investment decision targeted for early 2027. The project is progressing through front-end engineering and design, with ongoing efforts focused on capital efficiency, execution planning and strengthening its overall development framework.
Any final commitment will depend on market conditions, regulatory approvals and the companies’ internal investment processes. Shell has also emphasized that the project must meet its investment criteria and compete for capital against other opportunities across its portfolio.
Canadian Operations Strengthen Shell’s Strategic PositionThe acquisition adds to Shell’s broader Canadian investments, following its acquisition of ARC Resources and the approval of Phase 2 expansion at LNG Canada, in which Shell holds a 40% interest. Its Canadian portfolio also includes natural gas assets in British Columbia and Alberta, along with refining and fuel retail operations.
Bay du Nord could complement these existing businesses by adding exposure to a large offshore oil resource with long-term development potential. However, the project's benefits will depend on its ability to progress through regulatory and investment milestones and deliver attractive returns.
Overall, the proposed acquisition represents another step in Shell’s efforts to build a competitive energy portfolio. By securing a minority interest in Bay du Nord while leaving operational leadership with Equinor, Shell gains access to a potentially significant offshore resource while maintaining a disciplined approach to capital allocation. The upcoming investment decision will be crucial in determining the project’s path toward development and its eventual contribution to Shell’s Canadian operations.
SHEL and EQNR’s Zacks Rank & Other Key PicksBoth SHEL and EQNR are currently sporting a Zacks Rank #1 (Strong Buy).
Investors interested in the energy sector may consider some other top-ranked stocks like APA Corporation (APA - Free Report) and Canadian Natural Resources Limited (CNQ - Free Report) , each sporting a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Houston, TX-based APA Corp is engaged in the exploration, development and production of natural gas, crude oil and natural gas liquids. The Zacks Consensus Estimate for APA’s 2026 earnings indicates 56.2% year-over-year growth.
Calgary-based Canadian Natural Resources Limited is one of the largest independent energy companies in Canada engaged in the exploration, development and production of oil and natural gas. The Zacks Consensus Estimate for CNQ’s 2026 earnings indicates 59.5% year-over-year growth.
IREN ve fiskálním roce 2026 vykázala čistou ztrátu 702,6 milionu USD kvůli odpisům těžebního hardwaru při přechodu na infrastrukturu pro umělou inteligenci.
IREN Limited‘s (NASDAQ:IREN) transformation into an AI infrastructure provider could give it a more durable source of demand than Bitcoin (CRYPTO:$BTC) mining, but the transition comes with a different set of financial pressures.
The company is trading cryptocurrency-linked revenue for long-term computing contracts, while taking on the challenge of financing, building and operating infrastructure that AI customers increasingly need.
The shift is already visible in IREN’s financial results. In fiscal 2026, ended June 30, the company generated $578.2 million in Bitcoin mining revenue, compared with $128.8 million from AI Cloud Services, according to its annual results. AI Cloud revenue increased nearly eightfold from $16.4 million in fiscal 2025, while total revenue rose to $707 million from $501 million.
IREN is reallocating electricity and data-center capacity from mining equipment toward computing infrastructure used for AI training and inference, the process of running trained models to generate responses. In its 2026 annual filing, the company said it aims to substantially complete this transition by Dec. 31, 2026.
The opportunity is to turn existing power access and facilities into infrastructure that AI developers can use under longer-term contracts. But the financial results show that this is still a transition, not a completed transformation.
Read Next
The Cost of Changing Business ModelsIREN reported a $702.6 million net loss for fiscal 2026, compared with $86.9 million in net income a year earlier. Noncash impairment charges of $638.8 million, primarily related to decommissioning Bitcoin mining hardware as sites are converted for AI, weighed heavily on the result. Adjusted EBITDA, a measure of operating performance, also fell to $245.7 million from $269.7 million.
Those charges do not represent an equivalent cash outflow in the period, but they illustrate the cost of retiring equipment that no longer fits the company’s strategy. IREN must also finance new GPUs, data-center construction and the supporting infrastructure before all planned capacity generates revenue.
The company reported $4 billion in contracted annualized run-rate revenue for 2026 capacity, but only $1 billion was operating at the time of its August update. That distinction matters: contracted revenue represents business expected from signed agreements, while operating revenue depends on delivering usable capacity and serving customers.
Contracts Are Only Half the EquationIREN’s annual results also highlighted customer prepayments and GPU financing as ways to fund expansion. These arrangements can reduce the amount of upfront capital the company must provide itself, but financing does not eliminate construction, delivery or operating risks.
Investors should watch how quickly contracted capacity becomes operational revenue, whether AI Cloud margins improve and how much additional debt or equity the expansion requires.
IREN’s pivot could reduce its direct dependence on Bitcoin economics, but its success now depends on executing a capital-intensive infrastructure business — where demand is only valuable if the company can deliver capacity profitably.
Akcie společnosti USA Rare Earth v posledním obchodování klesly o 6 % a za poslední měsíc o 30 %, zatímco firma teprve očekává první vládní náhradu výdajů vázanou na splnění milníků.
Rare earth stocks are selling off hard as a group, and USA Rare Earth faces a particular squeeze with its government reimbursement money tied to milestones it has not yet hit. Whether that funding arrives before the spending pressure builds…
Rare earth stocks are falling as a group, and USA Rare Earth (NASDAQ:USAR) stock is among the worst hit while its milestone-based government funding is still ahead of it. USA Rare Earth stock is at $11.86, down 6% in recent trading. That loss adds to a steep slide and leaves USA Rare Earth stock down 30% over the past month.
Meanwhile, MP Materials (NYSE:MP) stock is falling alongside its smaller rival, down 6% to $43.45. By contrast, Critical Metals (NASDAQ:CRML) stock is holding up far better at $6.82 with just a 0.5% dip. Such a split leaves CRML stock as the steadiest of the three rare earth names.
Sector-wide pressure shows up in the fund data as well. The VanEck Rare Earth and Strategic Metals ETF (NYSEARCA:REMX) is at $58.15, down 5%. Broad-market trading is calm by comparison, with the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) at $777.95, down 0.1%.
Selling Concentrates in Rare Earth Names
USA Rare Earth hasn’t issued any announcement explaining the move. With the rare earth names and the sector ETF falling together while the S&P 500 fund sits close to unchanged, the selling is happening inside one group. MP Materials stock and USA Rare Earth stock are posting nearly identical losses, and both are steeper than the sector fund’s slide.
On the company’s August 10 results call, Chief Financial Officer Rob Steele described USA Rare Earth’s definitive agreements with the Department of Commerce as a milestone-based capital expenditure reimbursement program. Under that setup, the company gets reimbursed only after it reaches specific milestones. Steele said USA Rare Earth expected to apply for its first reimbursement distribution in the coming months, so the government money in the headline still lies ahead of the company.
Spending Runs Ahead of Revenue at USA Rare Earth
USA Rare Earth is building an integrated chain that runs from mining through processing to finished magnets. Its spending arrives years before the revenue that chain is meant to produce. MP Materials operates a producing mine at Mountain Pass. Its bull case is growing sales and a new aerospace and defense purchase deal, while the bear case is start-up costs from its magnet push. Critical Metals is a development-stage company with purchase term sheets for its Greenland project, but no operating revenue and substantial going concern doubt.
Covering the second quarter of 2026, USA Rare Earth reported revenue of roughly $6 million, capital expenditures of $66 million and cash of approximately $1.5 billion at period end. Set side by side, the spending exceeds the sales for the period, and that tension is central to the story.
The bearish case for USA Rare Earth starts with the structure itself, since reimbursement pays nothing until milestones are met. Round Top, the company’s main project, targets commercial operations in late 2028, and heavy spending against a small revenue base makes funding the central question.
On the bullish side, USA Rare Earth’s cash position is large, and the reimbursement structure ties public money to a supply chain the government wants built. A producer and a chain-builder falling by similar amounts in the same session shows the market marking the whole group lower, regardless of any one company’s progress.
What to Watch Next
What matters next for USA Rare Earth is whether its first reimbursement distribution is applied for and received. Traders may want to check for whether the company reports its first magnet sales, which would show the finished end of its chain producing revenue.
Each step would turn the funding in the headline from a promise into cash on the balance sheet. Until then, USAR stock investors should consider keeping their position sizes modest.
Contact [email protected] for any questions or corrections.
Společnost SanDisk zvýšila ve fiskálním roce 2026 tržby o 175 % na 20,3 miliardy USD díky nedostatku paměťových čipů a poptávce po infrastruktuře pro AI.
Since spinning off from Western Digital in February 2025, Sandisk (SNDK -6.39%) has become one of the biggest beneficiaries of the artificial intelligence (AI) infrastructure boom. Over the past year, Sandisk stock has soared 1,100%. In 2026 alone, its gain of 570% makes it the second best performer in the Nasdaq-100.
Yet despite its extraordinary price appreciation, Sandisk trades at a modest valuation. With memory shortages potentially extending through 2028, could Sandisk's valuation actually be too conservative?
Image source: The Motley Fool.
How the memory shortage is benefiting Sandisk
Sandisk specializes in NAND flash memory, a technology used to power solid-state drives, smartphones, computers, and storage systems. While Nvidia GPUs receive most of the attention surrounding AI chips, the enormous amounts of data generated by those accelerators must be stored somewhere. That's creating a powerful tailwind for storage suppliers.
During its late September earnings report, Micron Technology indicated that memory supply bottlenecks could persist through 2027 and 2028. This commentary aligns with Sandisk's management, which has previously highlighted how strong customer demand is limiting supply.
So far, the memory boom has made a dramatic financial impact on Sandisk. The company generated $20.3 billion in revenue during fiscal 2026, representing 175% year-over-year growth. Meanwhile, Wall Street expects fiscal 2027 revenue to approach $49 billion, more than doubling again. For a historically cyclical industry, these are encouraging growth numbers.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
-6.39
%) $
-101.04
Current Price
$
1,480.78
Sandisk's valuation still has room to expand
Wall Street expects Sandisk to generate approximately $215 in earnings per share during fiscal 2027. At a share price around $1,585, that translates into a forward price-to-earnings ratio of just 7.4. That looks inexpensive given the company's explosive revenue and profit growth.
SNDK Revenue (TTM) data by YCharts
It's important to note that memory manufacturers have historically traded at lower multiples because their profitability is more sensitive to supply and demand dynamics. When memory prices fall, earnings can erode surprisingly quickly.
But what if this AI-driven cycle is different? If AI infrastructure demand continues accelerating while NAND production remains constrained, Sandisk should enjoy unusually strong earnings for several years. This is what makes the company's shift toward multi-year customer agreements so savvy, as they provide more predictable revenue and earnings potential. In turn, growth investors could begin to assign Sandisk stock a higher valuation multiple.
Where could Sandisk stock trade by December?
In a downside scenario, investors may become concerned about weakening NAND prices or an eventual supply glut. If Sandisk were to trade at 5.5 times projected earnings, shares could retreat toward $1,182, representing about 25% downside to today's prices.
What I think is most realistic is Micron's supply outlook will prove accurate following Sandisk's upcoming earnings report on Oct. 29. At that time, investors could become more comfortable expanding the multiple. At nine times forward earnings, Sandisk would trade at approximately $1,935, implying 22% upside.
In a particularly bullish scenario, Sandisk's guidance could trigger both upward earnings revisions and multiple expansion. At 11 times projected earnings, Sandisk could approach $2,365, representing roughly 49% upside.
All told, I see a reasonable path toward $1,900 by year's end. Smart investors understand that Sandisk's modest valuation profile could reflect peak-cycle earnings rather than a genuine bargain. Nevertheless, secular tailwinds suggest Sandisk will continue benefiting from AI infrastructure demand and constrained memory supply. Against this backdrop, Sandisk looks like a compelling semiconductor stock to buy and hold as AI infrastructure continues to accelerate.
Ondas Holdings Inc. (NASDAQ:ONDS – Get Free Report) shares gapped up prior to trading on Monday. The stock had previously closed at $6.73, but opened at $7.06. Ondas shares last traded at $6.8110, with a volume of 10,973,743 shares traded.
Analyst Upgrades and Downgrades Several equities analysts have commented on the company. Citigroup began coverage on Ondas in a report on Monday, October 5th. They set a “market outperform” rating on the stock. LADENBURG THALM/SH SH lifted their price target on shares of Ondas from $21.50 to $22.75 and gave the company a “buy” rating in a research report on Monday, August 17th. Wall Street Zen cut shares of Ondas from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Oppenheimer upped their price objective on shares of Ondas from $16.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Finally, Weiss Ratings downgraded shares of Ondas from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.89.
Read Our Latest Stock Analysis on Ondas
Ondas Stock Performance The firm has a 50 day moving average of $7.95 and a two-hundred day moving average of $8.76. The stock has a market cap of $3.95 billion, a P/E ratio of -96.79 and a beta of 2.92. Ondas (NASDAQ:ONDS – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The business had revenue of $83.77 million during the quarter, compared to analyst estimates of $67.97 million. Ondas had a net margin of 93.55% and a negative return on equity of 14.20%. On average, sell-side analysts anticipate that Ondas Holdings Inc. will post -0.47 EPS for the current fiscal year.
Insider Activity at Ondas In other news, CFO Neil Laird sold 4,952 shares of the firm’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $7.74, for a total value of $38,328.48. Following the sale, the chief financial officer owned 42,246 shares in the company, valued at approximately $326,984.04. This trade represents a 10.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard Cohen sold 7,500 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $8.96, for a total transaction of $67,200.00. Following the transaction, the director directly owned 261,836 shares in the company, valued at $2,346,050.56. This trade represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.67% of the stock is currently owned by corporate insiders.
Institutional Trading of Ondas A number of hedge funds have recently bought and sold shares of ONDS. Beaird Harris Wealth Management LLC grew its position in Ondas by 3.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 27,250 shares of the company’s stock worth $266,000 after purchasing an additional 1,000 shares during the last quarter. State of Wyoming increased its holdings in shares of Ondas by 31.5% during the 1st quarter. State of Wyoming now owns 6,809 shares of the company’s stock worth $62,000 after purchasing an additional 1,631 shares during the period. NFSG Corp raised its position in shares of Ondas by 200.0% during the first quarter. NFSG Corp now owns 3,000 shares of the company’s stock valued at $27,000 after buying an additional 2,000 shares during the last quarter. Steadtrust LLC raised its position in shares of Ondas by 10.3% during the second quarter. Steadtrust LLC now owns 21,473 shares of the company’s stock valued at $177,000 after buying an additional 2,000 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Ondas by 5,373.7% during the first quarter. EverSource Wealth Advisors LLC now owns 3,120 shares of the company’s stock valued at $28,000 after buying an additional 3,063 shares during the last quarter. 37.73% of the stock is owned by institutional investors.
Ondas Company Profile (Get Free Report)
Ondas Holdings Inc (NASDAQ: ONDS) develops autonomous drone systems and private wireless networking solutions for industrial, government and critical-infrastructure applications. Its technologies are designed to support remote monitoring, inspection, security, public safety and other operations that require persistent data collection and reliable communications.
Through its subsidiaries, including American Robotics and Ondas Networks, the company offers autonomous drone platforms, command-and-control software, aerial intelligence solutions and industrial-grade wireless networks.
Further Reading Five stocks we like better than Ondas 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal 5 Retail Picks to Watch as the Holiday Shopping Season Nears Receive News & Ratings for Ondas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ondas and related companies with MarketBeat.com's FREE daily email newsletter.
Seagate's hard drives quietly power the AI boom without a single chip, and the stock already rewarded patient investors with a 261% gain in one year alone. Whether that momentum still has room to run depends on a few factors…
A $1,000 stake in Seagate Technology (NASDAQ:STX | STX Price Prediction) buys into a stock priced at $807.57 per share. That price comes after a 261.04% gain over the past year.
Seagate makes the mass-capacity hard drives that cloud giants fill with AI-generated data, so the question for 2030 is how much of that momentum can still turn into returns from here.
What $1,000 Could Become: Base-Case Answer The model’s longest horizon runs five years, to October 8, 2031. That is the nearest modeled horizon to 2030, so every concrete figure below is tied to it. Treat 2030 itself as an illustrative stop roughly a year short of the modeled target.
The base case suggests a $1,000 investment could be worth about $1,497.70 by the five-year mark, a total return of 49.77%. That outcome rests on a modeled share price of $1,209.52, which works out to 8.41% annualized. For a nearer checkpoint, the one-year base target of $908.18 (a 12.46% return) would lift the stake to $1,124.60.
Confidence in the model stands at 0.9, rated high. All of these figures cover share price only. Seagate’s $2.96 annualized dividend would come on top.
Bull, Base and Bear Scenarios for Your $1,000 Scenario Five-Year Target Price Total Return Value of $1,000 Bull $2,081.50 157.75% $2,577.50 Base $1,209.52 49.77% $1,497.70 Bear $703.09 -12.94% $870.60 Wall Street leans further toward the bull case than the model does. The consensus analyst target is $1,125, and the ratings break down to 4 Strong Buys, 18 Buys, 2 Holds and 1 Strong Sell. The model gives that analyst target a 0.3 weight and puts more weight on forward earnings, making its base case more conservative.
Three Drivers Behind the Upside Record Earnings and Rising Estimates Fiscal 2026 revenue reached $12.195 billion, up 34.06%, with EPS of $15.58 and a record $3.105 billion in free cash flow. In the fourth quarter, non-GAAP EPS came in at $5.71, beating the $5.09 estimate.
Management is guiding fiscal Q1 2027 to $7.30 ± $0.20 in EPS on revenue of $4.10B ± $100M. Analysts expect fiscal 2027 EPS of $35.7809 and fiscal 2028 EPS of $55.3714, and both figures sit above where they were 90 days ago.
Bigger Drives on the HAMR Roadmap Mosaic 4, Seagate’s second-generation HAMR platform, delivers “up to 44 terabytes per drive” with minimal change to the bill of materials.
Mosaic 5 is aimed at 50 terabytes, with qualification shipments targeted for late calendar 2027. Packing more capacity into each drive, rather than shipping more units, is the main reason gross margin rose to 52.3% from 37.4% a year earlier.
Demand Locked In Through 2027 Management says nearline capacity is “almost fully allocated through calendar 2027“. It also raised its annual revenue growth target to “a minimum of 20% over the next few years.”
The CEO put it this way: “As AI accelerates data generation and its value, we see durable long-term demand for mass capacity storage.” Seagate is one of the suppliers absorbing that AI buildout without actually making chips, and we rounded up seven more like it in a free report on the non-chipmaker AI stocks.
Risks That Could Shrink Your Stake Volatility is the first thing to plan for. Seagate’s beta is 2.081, and over the past 52 weeks the stock’s range spans $207.78 to $1,143.27. Hard drive stocks fell sharply late last week (as MarketWatch reported), leaving Seagate down 12.44% over one week.
Valuation leaves less room for mistakes. The stock trades at a trailing P/E of 58 and a forward P/E of 26. Growth also depends heavily on hyperscaler storage budgets. If cloud spending cools, or if a HAMR ramp runs into yield or qualification delays, earnings estimates could fall quickly.
Other pressures include tariff and trade policy, exposure to the Middle East conflict, possible dilution from the Exchangeable Senior Notes due 2028, and BIS settlement payments (per company disclosures). In the bear case, your $1,000 shrinks to $870.60.
Bottom Line on a $1,000 Seagate Position At the five-year horizon, the model’s range for a $1,000 Seagate stake runs from $870.60 in the bear case, reaching $2,577.50 in the bull case, with $1,497.70 as the base case.
Use 2030 as an illustrative waypoint on that path, and keep an eye on the stock around each earnings report and Mosaic milestone. The projection is not investment advice, and none of these outcomes is guaranteed.
Contact [email protected] for any questions or corrections.
